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Nephrin (NPHS1) is a key structural component of the slit diaphragm (SD) and common 
genetic variation of NPHS1 may influence SD function in diabetic nephropathy (DN). 
More recently, NPHS1 has also been reported in pancreatic β-cells and was involved in 
insulin secretion. Thus, common genetic variation of NPHS1 may be associated with type 
2 diabetes mellitus (T2DM) and its related traits. However, there are currently few 
studies investigating these potential roles of NPHS1. Therefore, this study investigated 
the association of NPHS1with both renal and T2DM-related traits. Six NPHS1 SNPs 
were genotyped in both the Singapore Diabetes Cohort Study and 1998 Singapore 
National Health Survey subjects. There was significant evidence for interaction of 
NPHS1 haplotypes with age on estimated glomerular filtration rate (eGFR) in T2DM 
patients. Specifically, with reference to the common haplotype, carriers of T/G/G/C/T/A 
and C/A/A/T/T/A had higher eGFR values among younger patients but had lower eGFR 
values among older patients. In contrast, carriers of T/G/A/T/T/G had lower eGFR values 
among younger patients with reference to the common haplotype. NPHS1 was generally 
not associated with any of the T2DM-related traits investigated. However, there was 
borderline association of waist-to-hip ratio (WHR) with SNPs rs437168 and rs17777002 
in the Chinese and Asian Indian populations respectively. In view of the studies 
implicating NPHS1 in β-cell function, this association with WHR is unexpected and its 
biological underpinning is less understood. In conclusion, our study has uncovered first 
evidence that NPHS1 may be potentially involved in the modulation of eGFR over time 
in patients with T2DM. This may have significant implication in our understanding of 
DN and its treatment. 
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CHAPTER ONE: INTRODUCTION 
1.1 Type 2 diabetes mellitus (T2DM) 
1.1.1 T2DM and its complications 
Diabetes mellitus (DM) is a major public health problem worldwide and its prevalence 
will continue to increase over the next few decades [1]. T2DM presents itself in the long 
run with an onslaught of macrovascular complications like cardiovascular disease and 
microvascular complications including retinopathy, neuropathy and nephropathy. All 
these complications cause much morbidity and mortality to T2DM patients. At least 90% 
of diabetic cases worldwide are comprised of T2DM and hence there is a great urgency to 
reduce these numbers and curb the progression of its associated complications [2].  
1.1.2 Prevalence of T2DM 
The International Diabetes Federation (IDF) has estimated that there are more than 360 
million people currently living with diabetes and this number is expected to rise to 552 
million by 2030 (Figure 1). The Western Pacific region where China, Asia and Singapore 
are located has the greatest number of cases than any other region in the world [3]. 
Among adults aged 18 to 69 years in Singapore, 11.3% were diagnosed to be diabetic in 
2010, a significant rise from 8.2% in 2004 [4].  




Figure 1. International Diabetic Federation (IDF) regions and global projections of the 
number of people with diabetes (20-79 years), 2010-2030. Reprinted from Diabetes Atlas 5
th
 
edition [3], with kind permission from IDF. 
 
1.1.3 T2DM-related traits and undiagnosed diabetes 
Impaired glucose tolerance (IGT) and impaired fasting glycemia (IFG) are T2DM-related 
traits which place individuals at a higher risk of progressing to T2DM [2]. Singapore falls 
into the region with the highest prevalence of individuals with IGT at more than 14% 
(Figure 2). It is estimated that around half of those who have diabetes are not aware of 
their condition, a situation which proves worrying since many of these individuals would 
have started developing related complications upon diagnosis. 




Figure 2. Comparative prevalence (%) of impaired glucose tolerance (20-79 years), 2011. 
Reprinted from Diabetes Atlas 5
th
 edition [3], with kind permission from IDF. 
 
1.2 Diabetic nephropathy (DN) 
DN is a major complication of T2DM and it currently accounts for more cases of end-
stage renal disease (ESRD) than any other cause of chronic kidney disease. It has been 
called a medical catastrophe of worldwide dimensions, likely due to an ever increasing 
prevalence of T2DM attributed to obesity, ageing and a sedentary lifestyle on one hand 
and improved survival resulting from better treatment for diabetic complications on the 
other [5, 6]. DN develops in about one third of diabetic patients [7]. Up to 63.5% of 
patients undergoing dialysis in Singapore are diabetic and this has been a disturbing 
upward trend over the years [8]. Patients with DN are at risk of progression to ESRD, by 
which time they would need to undergo dialysis or renal transplantation. Most of these 
patients do not receive the latter but depend on dialysis treatment for the rest of their lives 
which leads to a poor quality of life. Huge intervening efforts are needed to limit the 
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rising number of DN cases and this has fuelled an intense interest to search and discover 
markers for the early detection of DN.  
1.2.1 Clinical pathology of DN 
DN develops through several stages. In the earlier stages of DN, there is kidney 
hypertrophy where a thickened glomerular basement membrane (GBM), mild mesangial 
expansion and accumulation of hyaline in the arterioles are observed (Figure 3). 
Advanced nephropathy is characterised by the formation of Kimmelstiel-Wilson nodules, 
hyalinosis in both afferent and efferent arterioles and a markedly thickened GBM (Figure 
4) [9]. These dramatic structural changes prevent the glomerulus from performing its 
filtration function.  
Clinically, the onset of DN is characterised by a small to moderate increase in urinary 
albumin excretion (UAE) referred to as microalbuminuria and/or transient rise in 
glomerular filtration rate (GFR) called hyperfiltration. Without intervention, UAE rises 
dramatically to result in macroalbuminuria. GFR begins to decrease with this onset of 









Figure 3. A glomerulus with diabetic nephropathy characterised by nodular mesangial 
expansion (arrowhead) and hyalinosis of afferent and efferent arterioles (arrows). 




Figure 4. A glomerulus with a Kimmelstiel-Wilson nodule (arrowhead) which has 
completely occluded the glomerulotubular junction (thick arrow). Bowman's capsule is 
thickened and reduplicated. There is also hyalinosis of the arterioles (thin arrows). 
Reprinted from Najafian and Mauer [11], with kind permission from Elsevier. 
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1.2.2 Renal trait - GFR 
GFR provides a measurement of the filtering capacity of the kidneys. It estimates the 
amount of plasma filtered by all nephrons in both kidneys per minute. However, GFR 
cannot be measured directly.  
A substance that is inert, freely filtered at the glomerulus, but not secreted, reabsorbed, 
synthesised or metabolised by the kidney is a suitable candidate substance for GFR 
estimation as the amount of that substance filtered is equal to the amount excreted in the 
urine [12]. Inulin is one such substance and its clearance is currently the gold standard for 
measurement of GFR. Iohexol, technetium-labelled diethylene-triamine-penta-acetic acid 
and ethylene diamine-tetra-acetic acid are also able to achieve similar accuracy. 
However, measuring clearance using these methods is time consuming and costly 
especially for measurements done in a large number of individuals.  
Therefore, alternative methods have emerged. The surrogate for GFR measurements 
based on plasma creatinine is currently widely employed. The Cockcroft-Gault (CG) and 
Modification of Diet in Renal Disease (MDRD) formulae are two conventional equations 
that make use of creatinine clearance to estimate GFR and takes into account variables 
like age, sex, race and body size. The MDRD formula may perform better than the CG 
equation in adults but the data are limited [12]. However, the MDRD underestimates 
GFR if it is greater than 60ml/min/1.73m
2 
[13]. 
Cystatin C (CysC), unlike serum creatinine, is not secreted by proximal tubular cells and 
is thus less affected by extrarenal modulators. Equations have been derived to estimate 
GFR from CysC but proved to have no advantage over the MDRD in diabetic patients 
Chapter 1  Introduction 
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[10, 14]. At the moment, the MDRD formula is still widely used for the estimation of 
GFR in adult patients although newer equations are being derived including the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) [15, 16].  
In early diabetes, patients experience glomerular hyperfiltration (>140ml/min/1.73m
2
) 
and this is associated with a poor prognosis in the development of DN [17]. An increased 
plasma flow and intraglomerular pressure are established causes for hyperfiltration in 
early diabetes [18]. As duration of T2DM increases, estimated glomerular filtration rate 
(eGFR) declines gradually over the next 15 years before ESRD ensues by which time 
dialysis and renal transplantation are needed [19].  
1.2.3 Urinary marker of DN - albumin 
In normal individuals, very little albumin emerges in the urine. However, when there is 
renal damage, initially small amounts (microalbuminuria) and subsequently larger 
amounts (macroalbuminuria) of albumin excretion occurs. Microalbuminuria is a well-
established biomarker of DN.  UAE over a 24 h period is the current gold standard for 
determining the presence of microalbuminuria. However, this method is inconvenient and 
a more practical alternative like the random spot urine sample is sought. Although the 
latter method is susceptible to variation in urine concentration due to hydration, physical 
activity and other factors, nomalisation by dividing with creatinine concentration 
minimises some of these issues [20]. While a first morning void sample is a better 
alternative to 24 h collections than spot urine sample in the assessment of albuminuria, 
the spot urine sample for the measurement of albumin-to-creatinine ratio (ACR) is still 
widely used especially in out-patient diabetic clinics [15, 21, 22]. 
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The earliest clinical evidence of DN is most often microalbuminuria (UAE, 20-200 
µg/min in an overnight urine sample; ACR, 30-300 mg/g in a spot urine sample). 
Microalbuminuria affects 20-40% of patients 10-15 years after the onset of diabetes. 
Progression to macroalbuminuria (UAE, >200 µg/min; ACR,>300 mg/g) happens in 20-
40% of patients over 15-20 years after diabetes onset. Hypertension and 
macroalbuminuria are likely to hasten the decline in GFR and eventual ESRD [23].  
DN enters a vicious cycle once a certain degree of injury exists. Microalbuminuria 
triggers the progression of DN as continuous protein leakage overloads the tubular cells 
in the reabsorption pathway and this has been postulated to cause tubulointerstitial 
damage [24]. 
Encouragingly, remission to normoalbuminuria is possible with multifactorial 
intervention comprising intensive glycemic and blood pressure control in T2DM patients 
with microalbuminuria [25, 26]. However, with up to 50% undiagnosed diabetic patients 
and the asymptomatic nature of microalbuminuria, kidney damage may have started for a 
period of time before diagnosis and the opportunity for remission to normoalbuminuria 
could be less optimistic [26]. The transition from normal to micro- and on to 
macroalbuminuria is much more rapid than expected and possesses much heterogeneity 
among individuals [27].  When T2DM patients become macroalbuminuric, their renal 
function declines much more rapidly than in normoalbuminuric patients [28]. Hence, 
much focus is placed on the discovery of biomarkers which are able to provide early 
detection of DN. 
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1.2.4 Glomerular filtration barrier 
The glomerular filtration barrier is made up of three layers namely a fenestrated 
endothelium, GBM and the slit diaphragm (SD) (Figure 5). The SD is located between 
the interdigitating secondary foot processes of podocytes that cover the endothelial 




Figure 5. Cross sectional illustration of the glomerular filtration barrier. 
 
 




Figure 6. Scanning electron micrograph of a podocyte viewed from the urinary space and 
the spaces between the foot processes are the slit diaphragms (SDs). Reprinted from Smoyer 
and Mundel [29], with kind permission from Springer Science and Business Media. 
 
The fenestrae of the endothelium is permeable to water and small solutes but is 
impermeable to red blood cells. Furthermore, due to the expression of negatively charged 
glycoproteins, it repels very large anionic proteins like albumin. Similarly, the GBM 
functions as a charge-selective filter.  
The SD is made up of a zipper-like structure containing tiny pores [30].The extracellular 
domains of nephrin (NPHS1) interact with each other to form the structural scaffold of 
the SD (Figure 7) [31]. Other proteins like podocin (NPHS2), NPHS1 related protein 1 
(NEPH1), alpha-actinin 4 (ACTN4) and CD2-associated protein (CD2AP) associate with 
NPHS1 to form the SD complex [32-36].  




Figure 7. Simplified illustration of nephrin (NPHS1) assembly showing homophilic 
interaction of NPHS1 molecules from opposite foot processes at the centre of the SD. 











Chapter 1  Introduction 
12 
 
1.2.5 Genetics of DN 
Genetic susceptibility is a critical factor for the development and progression of DN. 
While the search for DN genes is ongoing, it is widely accepted that angiotensin-
converting enzyme (ACE) is the proto-typical DN gene [37]. 
The most common genetic variations in the human genome are single nucleotide 
polymorphisms (SNPs). These are sites in the DNA sequence where individuals differ at 
a single DNA base at a frequency of more than 1% in the population. Testing numerous 
individual SNPs along a candidate gene is a tedious and expensive process. On the other 
hand, haplotype analysis which takes into account multiple SNPs simultaneously could 
serve the same purpose with little loss of statistical power [38]. These SNPs may be 
selected according to the observation that some appear to be located in “blocks” which 
are regions with little historical recombination but demarcated by areas with an inferred 
high frequency of recombination events. A reduced set of tagging SNPs can then be 
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1.3 NPHS1 gene 
1.3.1 Congenital nephrotic syndrome of the Finnish type 
Congenital nephrotic syndrome of the Finnish type (CNF) is an autosomal recessive 
disorder that is caused by mutations in NPHS1. The common mutations are Fin-major 
and Fin-minor. CNF is characterised by massive proteinuria even in utero, indicating 
early damage of the glomerular filtration barrier that leads on to fatality in the first couple 
years of life unless renal transplantation is performed [40]. Compound heterozygotes for 
Fin-major/Fin-minor human fetal kidneys had an absence of NPHS1 expression and 
missing SDs while expression of other SD proteins like ZO-1 and P-cadherin were 
similar to normal kidneys [41]. In another study, homozygous Fin-major and compound 
heterozygous Fin-major/Fin-minor kidneys had no NPHS1 expression, podocytes 
exhibited fusion and SDs of irregular sizes were seen along with missing ones while ZO-
1 was detected in normal amounts [41].  
A variety of NPHS1 mutations have also been reported in patients with a spectrum of 
nephrotic disorders like focal segmental glomerulosclerosis (FSGS), steroid resistant 
nephrotic syndrome (SRNS) and minimal change nephrotic syndrome (MCNS) [42-44]. 
1.3.2 Experimental models 
NPHS1 gene inactivation by homologous recombination in embryonic stem cells of mice 
resulted in neonatal death within 24 h. Affected murine kidneys had enlarged Bowman’s 
spaces, dilated tubules, effacement of foot processes and missing SDs akin to that 
observed in CNF patients [45]. Absence of SDs and podocyte effacement was evident in 
NPHS1 knockout mice while expression of GBM (type IV collagen, laminin) and SD 
proteins (NPHS2, CD2AP, ACTN4) were not altered [46]. Similarly, mutant NPHS1 
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14 
 
mice generated by gene-trapping were proteinuric and died soon after birth but CD2AP 
and ZO-1 were unaltered [47]. Compared to wild type mice, NPHS1 deficient mice had 
fusion of foot processes and lacked SDs [47]. All these indicate that NPHS1 is a principle 
component of the SD structure and is crucial for the normal architecture and function of 
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1.3.3 Discovery of the NPHS1 gene 
A gene search was initiated in 1989 among Finnish families due to the high frequency of 
CNF in Finland. The candidate gene approach was unfeasible at that time because there 
were no known basement membrane genes that were localised to the critical region 
19q13.1. Positional cloning was the alternative approach and after years of combing the 
chromosomal region 19q13.1, the group finally pinned down the NPHS1 gene in 1998 
[32, 49].  
1.3.4 Structure of the NPHS1 gene 
NPHS1 has a size of 26,466 bp and contains 29 exons with sizes ranging from 25 to 216 
bp. The gene product, NPHS1, is a transmembrane protein that contains eight 
immunoglobulin (Ig) C2-like motifs. The first exon codes for the signal peptide, and 
exons 2-21 codes for the region containing the Ig domains. A fibronectin type III-like 
(FnIII) domain is encoded by exons 22-23 while exon 24 codes for the helical 
transmembrane domain. Exons 25-29 encode the intracellular domain and 3’untranslated 
region (UTR) [49, 50].  
1.3.5 NPHS1 structure 
NPHS1 is a putative member of the large Ig-like superfamily which comprises cell 
surface and soluble proteins that are involved in the recognition, binding or adhesion 
processes of cells [51]. It is a type 1 single pass membrane protein of 1241 amino acid 
residues with a theoretical molecular weight of about 137 kDa but an apparent molecular 
weight of 180 kDa on Western blot [52]. NPHS1 is composed of an extracellular domain 
with eight distal Ig-like domains and one proximal FnIII domain, a short helical 
transmembrane domain and an intracellular domain (Figure 8).  
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A major splice variant of NPHS1 called NPHS1-α has an identical sequence with NPHS1 
apart from a missing exon 24 which encodes the helical transmembrane portion of 
NPHS1 (Figure 9) [53]. NPHS1-α is potentially a secreted form of NPHS1 but its 
functional significance has not been elucidated. 
 
 




Figure 9. Protein structure of NPHS1 and NPHS1-α. 
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1.3.6 Impact of mutations on NPHS1 function 
More than 170 NPHS1 mutations have been reported to date [54]. In the Finnish 
population, 90% of CNF cases are of Fin-major (2 bp deletion in exon 2) and Fin-minor 
(nonsense mutation in exon 26) mutations [49, 50, 55]. These two mutations result in 
truncated forms of the protein. Other mutations that have been reported are missense 
mutations resulting in single amino acid substitutions which typically results in defective 
NPHS1 transport to the cell surface due to misfolding of the protein and are found 
accumulated in the endoplasmic reticulum [56]. An interesting missense mutation 
V882M results in the NPHS1 molecule being able to reach the cell surface but was 
restricted in lateral movement and trafficking at the plasma membrane [57].  
1.3.7 Primary and extrarenal NPHS1 expression 
The primary expression of NPHS1 is in the renal glomerulus, specifically in the 
podocytes and SDs (Figure 10). In rodents, the NPHS1 gene promoter was also found to 
be activated in the brain, spinal cord and β-cells of the pancreas [45]. In addition, 
expression of NPHS1 was detected in the testis, spleen and thymus [58]. Cardiac 
expression in human fetal and mouse hearts was also reported recently, and purportedly 
played a role in mouse heart development [59]. However, the only extrarenal expression 
of NPHS1 confirmed in adult humans is that found in the pancreatic β- and microvascular 
endothelial cells [60, 61]. Clinically, children with the two major mutations in NPHS1 do 
not have major defects in other organs except for the kidney. Minor neurological 
problems and mild cardiac hypertrophy are seen in these children but are most likely due 
to protein deficiency as a result of massive proteinuria [41]. However, subtle changes 
which do not give rise to obvious clinical defects should not be easily ruled out. 





Figure 10. Localisation of NPHS1 (arrowheads) on podocytes and SDs in a normal kidney. 
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1.4 DN and NPHS1 
1.4.1 In vitro studies 
NPHS1 expression was attenuated in most podocyte cell cultures exposed to a 
hyperglycemic environment.  Exposure of immortalised human podocytes to glycated 
albumin resulted in NPHS1 downregulation at the cell surface and NPHS1 mRNA 
expression was decreased by 42.6% in cells treated for 24 h. This phenomenon was 
absent in control cells that were treated with native albumin [62].  
1.4.2 Experimental models 
Several animal studies have generally shown that a reduction in NPHS1 expression in the 
glomerulus is predictive of albuminuria [63, 64]. Treatment with ACE inhibitors or anti-
inflammatory drugs rescued low NPHS1 expression and also reduced or prevented 
albuminuria [64, 65]. NPHS1 mRNA and protein expression was markedly low while 
UAE was significantly higher in streptozotocin (STZ)-induced diabetic rats compared to 
non-diabetic control rats [63, 64]. Interestingly, in another study, STZ-induced diabetic 
rats and non-obese diabetic mice both had increased levels of NPHS1 mRNA in the early 
stages and albuminuria was detected [66]. At present, it is unclear how the conflicting 
results should be reconciled but there are some who propose that an upregulation of 
NPHS1 could also disrupt the structure of the SD due to an upset of the stoichiometry of 
the proteins working together to form it [67].  
1.4.3 NPHS1 in kidneys of diabetic patients 
There are few studies investigating NPHS1 expression in human subjects due to the 
invasive nature of kidney biopsies. These results have to be interpreted with care as 
sample sizes are small and there may be bias in the selection of patients for biopsy. There 
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was a significant reduction in NPHS1 expression in the glomeruli of T2DM patients 
compared with control human renal cortex sections obtained from patients who 
underwent surgery for renal malignancy (62% reduction, P=0.0003) [68]. A markedly 
low NPHS1 expression was observed in the renal biopsies of type 1 diabetes mellitus 
(T1DM) and T2DM patients with DN compared to normal controls (up to 67% reduction, 
P<0.001). Similarly, T1 and T2DM patients with microalbuminuria also showed a 
reduction in NPHS1 staining compared to controls (up to 69% reduction, P<0.001) [62]. 
The proportion of cells with NPHS1 mRNA was substantially lower in 13 T2DM patients 
with DN compared to five non-diabetic MCNS patients as well as five normal controls 
[69]. Gene expression profiles of normal and DN kidneys revealed that a total of 96 genes 
were upregulated in DN while 519 genes, including NPHS1, were downregulated [70]. 
NPHS1 protein and mRNA expression were reported to be greatly reduced in diabetic 
patients in contrast with non-diabetic MCNS and normal control patients. However, 
protein and mRNA expression of CD2AP and NPHS2 were similar in all three groups of 
patients. There were also significantly fewer SDs in diabetic patients [71]. There was an 
apparent inverse relationship between the degree of NPHS1 expression and level of 
proteinuria in these studies.  
1.4.4 Nephrinuria 
The presence of NPHS1 was successfully detected in the urine of STZ-induced diabetic 
rats as early as week 4 after induction, implicating this molecule in early kidney damage. 
It can thus be inferred that NPHS1 is modulated in the early stages of kidney damage. In 
that study, nephrinuria corresponded to an increase of NPHS1 mRNA levels [66]. An 
increase in NPHS1 mRNA might have allowed for more protein to be available for 
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shedding into the urine. Alternatively, the sudden increase in NPHS1 expression could 
have disrupted the stoichiometry of SD proteins and resulted in nephrinuria [67]. 
Regardless, this finding raised the possibility of using nephrinuria as a biomarker of early 
kidney damage. 
Immunoreactive NPHS1 fragments were first detected in the urine of Finnish T1DM 
patients. It was observed that 28% of macroalbuminuric, 17% of microalbuminuric and 
30% of normoalbuminuric patients presented with nephrinuria while none of the non-
diabetic healthy controls were nephrinuric. Up to a third of normoalbuminuric diabetic 
patients have symptoms of filtration barrier damage as indicated by the manifestation of 
nephrinuria [72]. A subsequent study by Ng et al. (2011) found corroborating evidence 
for this earlier finding in Singaporean Chinese patients with T2DM. Furthermore, 
nephrinuria was found to be associated with a decline in eGFR even in normoalbuminuric 
patients [73]. A recent study also reported that 100% of micro- and macroalbuminuric 
Caucasian T2DM patients presented with nephrinuria while 54% of normoalbuminuric 
patients were nephrinuric [74]. These three studies highlighted the potential of 
nephrinuria as a predictor of early glomerular filtration barrier damage before its clinical 
manifestation as microalbuminuria. 
1.4.5 NPHS1 variants and DN 
There have been few studies looking at the association of NPHS1 SNPs with DN. Three 
exonic SNPs namely, rs3814995, rs33950747 and rs4806213 were investigated in 996 
Finnish T1DM patients for their association with DN. Results were largely negative [75]. 
The NPHS1 promoter region was sequenced in 100 Caucasian T2DM patients in search 
of genetic variants. However, none were found in all groups of patients (T2DM 
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normoalbuminuric, T2DM macroalbuminuric, non-diabetic controls with proteinuric 
nephropathies and healthy controls) [76]. An intronic SNP rs466452 was genotyped in 
231 Caucasian T1 and T2DM patients and there was an absence of association between 
the SNP and DN in both groups of patients [77].  
1.5 T2DM and NPHS1 
1.5.1 In vitro studies 
NPHS1 was expressed specifically both on the plasma membrane and the surface of 
insulin vesicles in the β-cells and promotes insulin secretion in response to glucose [78]. 
A higher expression of NPHS1 in mouse insulinoma 6 (MIN6) cells was associated with 
greater insulin content and improved glucose-stimulated insulin release (GSIR) compared 
to control cells. Downregulation of NPHS1 using small interfering RNAs resulted in 
insulin content and GSIR decrement in MIN6 cells in vitro. Additionally, NPHS1-
transfected cells had a markedly higher amount of secretory granules and secretory 
vesicles than control cells [78]. 
1.5.2 Experimental models 
In vivo, transplantation of NPHS1-positive MIN6 pseudoislets into diabetic mice caused a 
significantly lower glycemia and an earlier reversal to normoglycemia compared to mice 
which had MIN6 pseudoislets transfected with an empty vector. Diabetic mice became 
hyperglycemic again after removal of the kidney bearing the NPHS1-positive 
pseudoislets [78].  
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1.5.3 NPHS1 in pancreatic islets of diabetic patients 
NPHS1 expression in the pancreatic islets of T2DM cadaveric donors was reduced 
compared to age-, sex- and cold ischemia time-matched non-diabetic controls [78]. 
NPHS1 was inversely correlated with BMI (r
2
=0.75, P<0.001) but this was perhaps not 
unexpected since BMI was significantly higher in diabetic cases than non-diabetic 
controls.  
1.5.4 NPHS1 and insulin resistance in humans 
Although NPHS1 from the pancreas would unlikely be excreted in the urine, a 100 kDa 
urinary protein immunoreactive to an anti-NPHS1 antibody was found to be associated 
with insulin resistance in 128 offspring of T2DM patients compared to nine controls. 
Offspring with strongly positive 100 kDa bands were more insulin resistant in terms of 
reduced rates of non-oxidative glucose disposal than offspring who were weakly positive 
or negative for this 100 kDa band [79]. The identity of this band cannot be confirmed as 
its size does not fit the typical size profile of those immunoreactive NPHS1 fragments 
detected previously in T1DM patients [72]. However, the group explained that this 
protein could be a degradation product of full-sized NPHS1 due to incomplete protease 
inhibition. The usefulness of nephrinuria in the prediction of T2DM remains to be seen. 
1.5.5 NPHS1 variants with T2DM and T2DM-related traits 
The Funagata Study investigated the association of two exonic SNPs rs2285450, 
rs437168 and one intronic SNP rs2267588 with T2DM in Japanese patients [80]. The 
group found that all three SNPs were associated with T2DM. The frequencies of at-risk 
genotypes in the IGT and T2DM group were higher than the normal glucose tolerance 
(NGT) group [80]. This suggested that NPHS1 was not only associated with T2DM, but 
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potentially with T2DM-related traits like IGT as well. A single intronic SNP rs466452 
was studied in the Caucasians and an absence of association with both T1 and T2DM was 
reported [77].  
Experimental studies on the function of NPHS1 SNPs in the pancreatic islets are lacking. 
It is probable that certain NPHS1 variants cause NPHS1 in the β-cells to be 
downregulated which could result in IGT and eventual T2DM. The genetic involvement 
of NPHS1 in T2DM remains to be fully understood. 
1.6 Summary and rationale for present work 
1.6.1 NPHS1 and DN 
NPHS1 is essential for a healthy glomerular filtration system. It is a key structural 
component of the SD which is the last barrier to glomerular permeability.  The absence of 
NPHS1 as shown clinically in CNF patients and experimental models gave rise to severe 
proteinuria and proved to be fatal in the neonate. There are many common genetic 
variations ofNPHS1in the healthy population and these potentially play an important role 
in chronic kidney diseases, like DN. There are a few studies which investigated the 
association of NPHS1 SNPs with DN. However, none of the studies have thoroughly 
reported the associations of SNPs in the full length gene. All of them investigated a 
limited number of SNPs either in the exonic or intronic region and had a fairly small 
sample size. Moreover, these studies were done on Caucasian patients and their relevance 
to the Asian population is unclear.  
Hence there was a need to conduct a large study on Singaporean patients covering SNPs 
in the full length gene as well as substantial regions up- and downstream of the coding 
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region. In addition, genetic analysis involving the haplotypes would strengthen the 
findings of such a study, extending beyond that focused on single SNPs [38].  
1.6.2 NPHS1 and T2DM 
Extrarenal NPHS1 expression has been reported in the pancreatic β-cells of humans. 
NPHS1 was found to be localised to the plasma membrane and surface of insulin vesicles 
of the β-cells. A role of NPHS1 in the pathway of insulin exocytosis has been 
demonstrated using in vitro and in vivo methods. A greater NPHS1 expression translated 
to higher insulin content in cells and significantly lowered glycemia in mice. All these 
findings were consistent with the observation that NPHS1 expression was lower in islets 
of T2DM patients compared to non-diabetic controls in the same study [78]. Although 
this is the only study which has demonstrated the role of NPHS1 in insulin secretion, the 
evidence presented from human, animal and cell culture investigations seem to strongly 
implicate NPHS1in insulin secretion and thus β-cell function. Furthermore, an earlier 
study in Japanese had detected the association of three NPHS1 variants with T2DM [80]. 
While these results were encouraging and potentially suggested that NPHS1 may have a 
vital role to play in the pathophysiology of the development of T2DM, reports of genetic 
replication have not been forthcoming. Therefore this present study seeks to examine the 
association of NPHS1 SNPs in the full length gene with T2DM-related traits as well as 
T2DM in Singaporeans. 
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1.6.3 Aims of study 
Aim 1: To investigate the association of NPHS1 SNPs with renal traits including eGFR 
and albuminuria in T2DM Chinese patients in Singapore. These patients were from the 
Singapore Diabetes Cohort Study (SDCS) described in Methods 2.1.1. 
Aim 2: To investigate the association of NPHS1 SNPs with T2DM-related traits in non-
diabetic Chinese, Malay and Indian subjects in Singapore. These subjects were from the 
1998 Singapore National Health Survey (NHS98) described in Methods 2.1.2. 
Aim3: To investigate the association of NPHS1 SNPs with T2DM in Chinese subjects in 
Singapore. Cases with T2DM were from both the SDCS and NHS98 (Methods 2.1.1 and 
2.1.2) and non-diabetic controls were from the NHS98 (Methods 2.1.2). 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Patient populations 
2.1.1 Singapore Diabetes Cohort Study (SDCS) 
T2DM patients included in this study were from patients recruited into the SDCS. Both 
the National University of Singapore Institutional Review Board (NUS-012) and the 
National Healthcare Group Domain-Specific Review Board (C/05/118) approved the 
research protocol and patients participating in this study gave informed consent. Briefly, 
since 2004 all patients previously diagnosed with T2DM and who were being treated at 
primary care facilities of the National Healthcare Group Polyclinics (NHGP) in 
Singapore were invited to join the SDCS. Of the patients approached, 91% agreed to 
participate in the study and formed a part of our SDCS patient group. Consenting patients 
completed a questionnaire to elicit information on demographics, lifestyle factors and 
family medical history. They also had their physical measurements taken. Medical 
records were reviewed to obtain information on their metabolic control and the presence 
of comorbidities and complications. Genotype data were only available for Chinese 
patients in this part of the study (n=1363). 
2.1.2 1998 Singapore National Health Survey (NHS98) 
NHS98 is a population based, cross-sectional study comprising Chinese, Malays, and 
Asian Indians aged between 18 and 69 years. Previously described survey methods were 
based on the World Health Organization (WHO) recommended model for field surveys 
of diabetes and other non-communicable diseases, and the WHO Multinational 
Monitoring of Trends and Determinants in Cardiovascular Disease protocol for 
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population surveys [80]. At the time of this study, DNA samples from 2953 Chinese, 792 
Malay, and 603 Asian Indian subjects were available for analysis (n=4348). 
2.1.3 Laboratory methods 
2.1.3.1 Albumin and creatinine measurements 
Spot urine samples were collected at the centre of recruitment. Sample aliquots were 
stored in the -80
o
C freezer until needed. When required, aliquots were thawed in an ice 
bath before centrifugation at 13000 rpm for 5 min to spin down all the sediments. Urine 
from the supernatant was used to measure albumin concentration by employing a 
competitive enzyme-linked immunosorbant assay (ELISA) (Albuwell II Albumin ELISA 
kit; Exocell Inc., Philadelphia, PA, USA). Likewise, creatinine concentration was 
determined by using a chemical colorimetric assay (The Creatinine Companion; Exocell 
Inc., Philadelphia, PA, USA) following the manufacturer’s protocol. The albumin value 
(mg) was divided by the creatinine value (g) to obtain the albumin-to-creatinine ratio 
(ACR) (mg/g). 
2.1.3.2 DNA extraction 
Venous blood samples were collected and centrifuged at 3500 rpm for 15 min to separate 
blood into three layers namely plasma, buffy coat and red blood cells. All three layers 
were stored as aliquots in a -80
o
C freezer until required. DNA were isolated from blood 
samples using DNA blood Midi kits (QIAGEN, Hilden, Germany) following the 
manufacturer’s protocol. 
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2.1.3.3 Estimated GFR 
Renal function was estimated by the simplified MDRD equation [82]: 
eGFR= 186.3× (plasma creatinine in μmol/L ×0.011)−1.154×(age in years)−0.203×0.742 for 
women × 1.21 if the individual is black 
2.1.3.4 Plasma glucose and insulin measurements*  
Fasting blood samples were drawn for measurement of plasma glucose (Boehringer 
Manheim, Mannheim, Germany) and insulin (immunoassay using an Abbott AxSYM; 
Abbott Laboratories, Chicago, Illinois) in NHS98 subjects after fasting overnight for at 
least 10 h.  
2.1.3.5 Oral glucose tolerance test*  
NHS98 participants, except diabetic subjects on oral hypoglycemic agents or insulin, had 
an oral glucose tolerance test (OGTT). Subjects were considered to have T2DM if they 
gave a history of T2DM or if their fasting glucose was ≥7.0 mmol/L or if their OGTT 
was ≥11.1 mmol/L. IFG was defined as fasting glucose between 6.0 to 7.0 mmol/L and 
OGTT <7.8 mmol/L, and IGT was defined as fasting glucose >7.0 mmol/L and OGTT 
between 7.8 to 11.1 mmol/L. 
2.1.3.6 Physical measurements* 
Blood pressure, height, weight, waist and hip circumference were measured for all 




* Measurements and tests were performed by staff of the NHGP. 
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2.1.3.7 Homeostatic model assessment  
Homeostatic model assessment (HOMA) for insulin resistance and β-cell function were 
calculated respectively based on the following equations [83]: 
HOMA-insulin resistance = (FPI × FPG) ÷ 22.5 
HOMA-β-cell function = (20 × FPI) ÷ (FPG - 3.5) % 
where FPI is fasting plasma insulin concentration (mU/L) and FPG is fasting plasma 
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2.1.4 Selection of NPHS1 SNPs 
NPHS1 SNPs rs2267588 and rs33950747 were studied in the Japanese and Caucasian 
respectively in relation to diabetes but lacked genotype data in the Han Beijing Chinese 
samples (CHB) from HapMap [75, 80]. They were assessed for their degree of 
polymorphism before the decision to include or exclude them from the genotyping 
exercise was made. The traditional restriction fragment length polymorphism method was 
employed for this purpose and it was found that these two variants were not polymorphic 
in the CHB samples. Therefore, they were excluded from further analysis. 
For haplotype analysis, genotypic data of 30 SNPs in the chromosomal region Chr19: 
41003706..41039579 (encompassing NPHS1 gene as well as 5 kb up- and downstream of 
it) belonging to the CHB population were obtained from the HapMap Genome Browser 
release #27 (www.hapmap.org). 14 of the SNPs were non-polymorphic (minor allele 
frequency <0.05) and were excluded. Pairwise linkage disequilibrium (LD) was therefore 
measured in the remaining 16 SNPs between each SNP and its nearest neighbour as 
proposed by Gabriel et al. (2002) [38] (Table 1). 15 SNPs with Lewontin’s |D’|>0.8 were 
located in haplotype blocks while rs10409299 (M7) which was not in strong LD with its 
neighbouring SNPs was treated as a singleton (Tables 2 and 3). Five tagging SNPs were 
needed to capture the haplotype diversity within the blocks. Together with the singleton, 
rs10409299, a total of six SNPs were genotyped in the SDCS and NHS98 samples. 
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Table 1. 16 biallelic SNPs selected for LD and haplotype block analyses. 
Marker SNP ID Location Marker SNP ID Location 
M1 rs17777002 Downstream M9 rs2073901 Exon 17 
M2 rs11084831 Intron 28 M10 rs7248157 Intron 16 
M3 rs460560 Intron 28 M11 rs392702 Exon 11 
M4 rs731934 Intron 27 M12 rs3814995 Exon 3 
M5 rs2071327 Exon 26 M13 rs2285450 Exon 3 
M6 rs4806213 Exon 24 M14 rs401824 Promoter 
M7 rs10409299 Intron 23 M15 rs443186 KIRREL2 5'UTR 
M8 rs437168 Exon 17 M16 rs435605 KIRREL2 5'UTR 
 
Table 2. Haplotype block 1. 
No. M1 M2 M3 M4 M5 M6 Freq 
1 A G C G C T 0.103 
2 A G T G C T 0.161 
3 A T T A T T 0.619 
4 G T T A T T 0.111 
            Total 0.994 
*Markers M1 (rs17777002), M3 (rs460560) and M5 (rs2071327) were selected from Block 1 to 
be genotyped. 
 
Table 3. Haplotype block 2. 
No. M8 M9 M10 M11 M12 M13 M14 M15 M16 Freq 
1 A G A G C A G C T 0.054 
2 G G G G C G A A T 0.177 
3 G G G G T G A A T 0.667 
                  Total 0.899 
*Markers M8 (rs437168) and M12 (rs3814995) were selected from Block 2 to be genotyped. 




The six SNPs were genotyped using short amplicon-based high resolution DNA melting 
assays. Each primer pair was designed by Primer 3 software 
(http://frodo.wi.mit.edu/primer3/) (Table 4). The PCR conditions were: initial 
denaturation performed at 95 °C for 2 min, followed by 50-65 cycles of denaturation at 
98 °C for 20 s, annealing at respective temperature for 15 s, extension at 68 °C for 30 s, 
and final extension at 68 °C for 5 min. To maximise the incorporation of double stranded 
DNA-binding dye, LC-green Plus (Idaho Technology Inc., Salt Lake City, UT, USA), all 
samples were subjected to an additional denaturation at 95 °C for 30 s and annealing at 
25 °C for 30 s after the final extension step. Fluorescence monitoring during thermal 
denaturation from 45 °C to 98 °C was done immediately using LightScanner (Idaho 
Technology Inc.). Genotyping success rate was more than 95% for all six SNPs. 
Table 4. Genotyping conditions for NPHS1 SNPs using high resolution DNA melting. 






































GACCAG 62 100 
     TA= Annealing temperature 
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2.1.6 Statistical analysis 





 percentile) for skewed data. Differences in characteristics among 
groups were compared using the χ2 test for categorical variables. For continuous variables 
that were normally distributed, analysis of variance was used to compare differences in 
mean among groups. Otherwise, the non-parametric Kruskal-Wallis test was implemented 
and the medians were compared.  
Hardy-Weinberg equilibrium (HWE) tests and estimation of LD strength for the SNPs were 
both performed using Haploview version 4.2 (http://www.broadinstitute.org/) [84]. 
Distribution of ACR was skewed hence natural logarithmic transformation was performed 
for the purpose of analysis. SNP association analyses for DN according to ACR were 
calculated using logistic regression reporting odds ratio. An additive genetic model was 
assumed where individuals were assigned as 0/1/2 according to the number of minor alleles. 
SNP association analyses for lnACR and eGFR traits were performed using linear 
regression assuming an additive model of inheritance.  
The haplotype analyses were performed using haplo.glm function in R package haplo.stats 
(http://cran.stat.nus.edu.sg/). Haplotype frequency cut-off was set at 5%. The posterior 
probabilities of pairs of haplotypes for each subject were estimated using the maximum 
likelihood method and the estimated probabilities were subsequently used as weights in the 
regression model with lnACR or eGFR as dependent variables, and haplotypes and 
environmental variables as independent variables. Interaction between haplotypes and the 
environmental variable (e.g. age and DM duration) was investigated and significant 
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interactions were retained in the regression model. Haplotype association analysis with DN 
according to albuminuric status was performed using haplo.score function in R. Effects of 
statistically significant confounders were adjusted for by including the confounders in the 
regression model.  
The T2DM-related traits that were considered were BMI, waist-to-hip ratio (WHR), 
fasting glucose, fasting insulin, HOMA-insulin resistance and HOMA-β-cell function. 
The distributions of fasting glucose, fasting insulin, HOMA-insulin resistance and 
HOMA-β-cell function were not normally distributed and were presented as geometric 
mean (range) as recommended [83]. Skewed values were normalised by natural 
logarithmic transformation for regression analysis and subsequently back transformed for 
presentation. SNP association analyses for T2DM-related traits were performed using 
linear regression assuming an additive genetic model. SNP association analyses for 
T2DM according to glucose tolerance status were performed using logistic regression. 
Analyses were stratified according to ethnic group and adjusted for age and gender. BMI 
and HOMA-insulin resistance were additionally adjusted for when testing SNP 
association with HOMA-β-cell function [83]. 
Haplotype association analysis with T2DM according to glucose tolerance status was 
performed using haplo.score function in R. Effects of potential confounders which were 
significantly different among the case-control groupings were adjusted for by including 
them in the statistical models. 
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For all statistical analyses, type I error was set to 5%. In order to mimimise false positive 
findings, Bonferroni correction for multiple comparisons was made according to the number 
of SNPs or haplotypes tested. All statistical analyses were performed using Stata V.11 
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CHAPTER 3: RESULTS 
3.1 Aim 1 
To investigate the association of NPHS1 SNPs with renal traits including eGFR and 
albuminuria in T2DM Chinese patients in Singapore. These patients were from the SDCS 
described in Methods 2.1.1. 
Only genotype data of Chinese subjects from the SDCS were available. This formed a 
case-control study where T2DM subjects were grouped according to their albuminuric 
status (stages of DN): controls were normoalbuminuric (ACR<30mg/g) and cases were 
microalbuminuric (30≤ACR<300mg/g) and macroalbuminuric (ACR≥300mg/g). SNP 
and haplotype association analyses with stages of DN were performed. Treating the renal 
traits, lnACR and eGFR as continuous variables, their association with NPHS1 SNPs and 
haplotypes were also investigated.  
3.1.1 Clinical characteristics of SDCS subjects 
Subjects were grouped according to albuminuric status. There were 870 
normoalbuminuric controls, 339 microalbuminuric and 95 macroalbuminuric cases 
(Table 5). There were 59 patients with missing ACR values who were excluded from 
analysis but subsequently included for eGFR analysis. The three groups were similar in 
terms of gender composition, body mass index (BMI), diastolic blood pressure (DBP), 
high density lipoprotein (HDL) levels and the proportion of patients taking lipid lowering 
medication. The cases were slightly older, had marginally higher waist-to-hip ratio 
(WHR), systolic blood pressure (SBP), triglycerides, total cholesterol and low density 
lipoprotein (LDL) levels (P<0.05). Cases also had a significantly longer median duration 
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of diabetes, higher glycatedhaemoglobin (HbA1c) levels, lower eGFR and a greater 
proportion of individuals on antihypertensive and diabetes medication (P<0.0001).  
Table 5.Clinical characteristics of SDCS patients stratified by albuminuric status. 
 CTRLS MICRO MACRO P 
Number (n) 870 339 95  
Male gender, n (%) 432 (49.7) 183 (54.0) 45 (47.4) 0.323 
     
At enrolment     
Age (years) 63.3 (9.1) 64.9 (10.2) 66.1 (11.3) 0.007 
Body mass index (kg/m
2
) 25.2 (3.7) 25.8 (4.1) 25.5 (4.1) 0.158 
Waist-to-hip ratio 0.90 (0.07) 0.91 (0.07) 0.91 (0.07) 0.012 
Diabetes duration (years) 5.5 (2-12) 8 (3-17) 10 (4-18) <0.0001 
Haemoglobin A1c(%) 7.26 (0.94) 7.51 (1.05) 7.79 (1.47) <0.0001 
Systolic blood pressure (mmHg) 133.66 (12.25) 134.52 (12.12) 139.25 (14.33) 0.001 
Diastolic blood pressure (mmHg) 77.32 (7.56) 77.40 (7.46) 79.08 (8.92) 0.302 
Triglyceride (mmol/L) 1.42 (0.78) 1.56 (0.74) 1.63 (0.76) 0.004 
Total cholesterol (mmol/L) 4.69 (0.75) 4.76 (0.76) 4.87 (1.18) 0.005 
High density lipoprotein (mmol/L) 1.28 (0.33) 1.23 (0.36) 1.22 (0.35) 0.145 
Low density lipoprotein (mmol/L) 2.78 (0.64) 2.84 (0.63) 2.88 (1.01) 0.005 
eGFR (ml/min/1.73m
2
) 80.54 (21.61) 75.24 (23.18) 68.88 (25.77) <0.0001 
Antihypertensive medication (Y/N) 702/154 295/41 85/9 <0.0001 
Lipid lowering medication (Y/N) 741/115 281/55 81/13 0.862 
Diabetes medication (Y/N) 639/219 283/53 81/14 <0.0001 






CTRL, normoalbuminuriccontrols; MICRO, cases with microalbuminuria; MACRO, cases with 
macroalbuminuria 
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3.1.2 HWE and LD of NPHS1 SNPs in SDCS subjects 
Genotype data was available for 1363 Chinese patients from SDCS at the time of this 
study. All six SNPs did not deviate from that expected under HWE among SDCS 
subjects as well as among subjects stratified by albuminuric status (Supplementary 
Tables 1 and 2). As expected, the six SNPs were in low LD with each other 
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3.1.3 NPHS1 and albuminuria 
3.1.3.1 Association of NPHS1 SNPs with stages of DN 
All six common variants of NPHS1 were not associated with DN in the additive genetic 
model with adjustment for significant clinical covariates (Table 6). The dominant and 
recessive models of inheritance also did not reveal any significant associations 
(Supplementary Tables 4 and 5). 
 
Table 6. Association of NPHS1 SNPs with stages of DN (additive model). 







(2) vs (1) 
P* 
(3) vs (1) 
P* 
OR (95% CI) OR (95% CI) 
         
rs3814995 TT 311 (36.6) 126 (37.9) 34 (36.6)     
 CT 399 (46.9) 159 (47.9) 47 (50.5) 0.95 (0.78-1.17) 0.628 0.97 (0.67-1.41) 0.889 
 CC 140 (16.5) 47 (14.2) 12 (12.9)     
rs437168 GG 613 (71.0) 244 (72.4) 72 (76.6)     
 AG 225 (26.1) 86 (25.5) 19 (20.2) 0.81 (0.61-1.08) 0.155 0.70 (0.41-1.20) 0.193 
 AA 25 (2.9) 7 (2.1) 3 (3.2)     
rs10409299 AA 469 (55.4) 189 (57.8) 50 (53.2)     
 AG 321 (37.9) 117 (35.8) 37 (39.4) 0.96 (0.76-1.21) 0.725 1.17 (0.78-1.76) 0.437 
 GG 57 (6.7) 21 (6.4) 7 (7.4)     
rs2071327 TT 340 (40.4) 144 (43.1) 39 (41.5)     
 CT 387 (46.0) 157 (47.0) 44 (46.8) 0.87 (0.70-1.08) 0.207 0.96 (0.66-1.40) 0.828 
 CC 115 (13.7) 33 (9.9) 11 (11.7)     
rs460560 TT 746 (87.2) 299 (89.3) 85 (91.4)     
 CT 108 (12.6) 36 (10.7) 8 (8.6) 0.83 (0.54-1.28) 0.380 0.59 (0.25-1.44) 0.251 
 CC 2 (0.2) 0 (0.0) 0 (0.0)     
rs17777002 AA 671 (79.2) 267 (80.2) 76 (81.7)     
 AG 167 (19.7) 61 (18.3) 17 (18.3) 0.95 (0.69-1.31) 0.763 0.79 (0.73-1.45) 0.440 
 GG 9 (1.1) 5 (1.5) 0 (0.0)     
                  *Adjusted for age, WHR, DM duration, HbA1c%, SBP, triglycerides, cholesterol, LDL, eGFR, 
antihypertensive medication and diabetes medication. 
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3.1.3.2 Association of NPHS1 SNPs with lnACR 
None of the SNPs were associated with lnACR across all patients with or without 
adjustment for significant clinical covariates (Table 7).  
 
Table 7. Association of NPHS1SNPs with lnACR among all patients. 
SNP Genotype N Mean (SD) 95% CI P P* 
rs3814995 TT 471 2.93 (1.67) 2.78 - 3.08 0.492 0.602 
 CT 605 2.96 (1.67) 2.82 - 3.10   
 CC 199 2.80 (1.58) 2.58 - 3.02   
rs437168 GG 929 2.95 (1.68) 2.85 - 3.06 0.246 0.052 
 AG 330 2.88 (1.59) 2.71 - 3.06   
 AA 35 2.61 (1.74) 2.01 - 3.21   
rs10409299 AA 708 2.90 (1.65) 2.78 - 3.02 0.455 0.211 
 AG 475 2.96 (1.66) 2.81 - 3.11   
 GG 85 3.00 (1.79) 2.61 - 3.39   
rs2071327 TT 523 2.96 (1.64) 2.82 - 3.10 0.540 0.800 
 CT 588 2.94 (1.68) 2.80 - 3.08   
 CC 159 2.86 (1.62) 2.61 - 3.12   
rs460560 TT 1130 2.96 (1.67) 2.86 - 3.05 0.112 0.127 
 CT 152 2.75 (1.59) 2.49 - 3.00   
 CC 2 2.12 (0.16) 0.67 - 3.57   
rs17777002 AA 1014 2.96 (1.67) 2.86 - 3.06 0.262 0.216 
 AG 245 2.81 (1.59) 2.62 - 3.01   
  GG 14 2.93 (1.83) 1.87 - 3.99     
*Adjusted for DM duration, HbA1c%, SBP, cholesterol, HDL and eGFR. 
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3.1.3.3 Association of NPHS1 haplotypes with stages of DN 
With reference to the common haplotype T/G/A/T/T/A, none of the haplotypes showed 
significant association with stages of DN (Table 8). 
 
Table 8. Association of NPHS1 haplotypes with stages of DN. 
       (2) vs (1) (3) vs (1) 










95%CI Specific Global Specific Global 
T/G/A/T/T/A 33.0 29.9-36.2 34.8 29.7-40.1 32.4 23.4-43.0 0.705 0.746 0.636 0.884 
T/G/A/T/T/G 5.2 3.9-7.0 5.6 3.4-8.6 7.6 3.0-14.6 0.633  0.808  
T/G/G/C/T/A 15.1 12.7-17.6 15.6 11.9-19.9 17.5 10.8-27.1 0.858  0.336  
C/G/A/T/T/A 14.4 12.1-16.9 16.8 13.0-21.2 18.2 10.8-27.1 0.126  0.143  
C/A/A/T/T/A 7.0 5.4-8.9 6.4 4.1-9.7 5.6 1.7-11.9 0.470  0.314  
Total 74.7  79.2  81.3      
*Adjusted for age, WHR, DM duration, HbA1c%, SBP, triglycerides, cholesterol, LDL, eGFR, 
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3.1.3.4 Association of NPHS1 haplotypes with lnACR 
The cut-off frequency for haplotype analysis was set at 5% and five haplotypes were 
obtained (Table 9). These haplotypes account for 76% of all haplotypes. Haplotypes of 
NPHS1 were generally not associated with lnACR. One haplotype C/G/A/T/T/A showed 
borderline association but this did not remain significant after taking into account of 
multiple comparisons. 
 
Table 9. Association of NPHS1haplotypes with lnACR among all patients. 
Haplotype Freq (%) Mean (se) of lnACR 95%CI P* 
        Specific Global 
T/G/A/T/T/A 33.4 2.80 (0.7) 1.45 - 4.16 0.916 0.336 
T/G/G/C/T/A 15.3 2.97 (0.7) 1.60 - 4.35 0.177  
C/G/A/T/T/A 15.2 3.03 (0.7) 1.66 - 4.41 0.049  
C/A/A/T/T/A 6.7 2.68 (0.7) 1.29 - 4.08 0.122  
T/G/A/T/T/G 5.4 2.92 (0.7) 1.52 - 4.32 0.706   
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3.1.3.5 Interaction of NPHS1 haplotypes with age on lnACR 
The potential for haplotype interactions with patient characteristics on lnACR were 
investigated. Particularly, we focused on age and DM duration. Using the most common 
haplotype as the reference, none of the remaining haplotypes showed significant 
interaction with age (Table 10). Rare haplotypes grouped as a single category exhibited 
significant interaction but this could not be interpreted meaningfully (P=0.004, 
Pcorrected=0.024).  
 
Table 10. Interaction of NPHS1 haplotypes with age on lnACR. 
Haplotype Freq (%) 
Slope/unit  
age (yrs) 
95% CI P* 
T/G/A/T/T/A 33.3 -0.013 -0.040;0.013 (reference) 
T/G/G/C/T/A 15.3 0.003 -0.037;0.043 0.279 
C/G/A/T/T/A 15.3 0.003 -0.036;0.042 0.249 
C/A/A/T/T/A 6.7 -0.034 -0.083;0.014 0.312 
T/G/A/T/T/G 5.4 -0.014 -0.058;0.029 0.946 
Rare N/A 0.014 -0.018;0.047 0.004 
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3.1.3.6 Interaction of NPHS1 haplotypes with DM duration on lnACR 
Relative to the common haplotype, none of the remaining haplotypes showed any 
significant interaction with DM duration on lnACR (Table 11). 
 
Table 11. Interaction of NPHS1 haplotypes with DM duration on lnACR. 
Haplotype Freq (%) 
Slope/unit  
DM duration (yrs) 
95% CI P* 
T/G/A/T/T/A 33.3 0.012 -0.016;0.039 (reference) 
T/G/G/C/T/A 15.3 0.020 -0.018;0.057 0.544 
C/G/A/T/T/A 15.2 0.035 -0.006;0.076 0.127 
C/A/A/T/T/A 6.7 0.028 -0.020;0.076 0.408 
T/G/A/T/T/G 5.4 0.018 -0.034;0.069 0.780 
Rare N/A 0.012 -0.022;0.047 0.934 
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3.1.4 NPHS1 and eGFR 
3.1.4.1 Association of NPHS1 SNPs with eGFR 
None of the SNPs were associated with eGFR across all patients with or without 
adjustment for significant clinical covariates (Table 12).  
Table 12. Association of NPHS1SNPs with eGFR among all patients. 
SNP Genotype N Mean (SD) 95% CI P P* 
rs3814995 TT 492 77.77 (22.40) 75.79 - 79.76 0.702 0.724 
 CT 627 78.70 (23.61) 76.85 - 80.55   
 CC 208 78.15 (20.44) 75.36 - 80.94   
rs437168 GG 965 78.48 (22.42) 77.07 - 79.90 0.559 0.366 
 AG 343 77.63 (23.68) 75.11 - 80.14   
 AA 40 77.68 (21.45) 70.82 - 84.54   
rs10409299 AA 732 78.05 (22.78) 76.40 - 79.70 0.613 0.366 
 AG 502 78.42 (22.34) 76.46 - 80.38   
 GG 88 79.32 (22.85) 74.48 - 84.17   
rs2071327 TT 539 77.69 (22.28) 75.80 - 79.57 0.426 0.473 
 CT 620 78.17 (23.32) 76.33 - 80.01   
 CC 164 79.39 (21.65) 76.05 - 82.72   
rs460560 TT 1176 78.13 (22.62) 76.84 - 79.43 0.979 0.390 
 CT 159 77.69 (23.14) 74.06 - 81.31   
 CC 2 96.68 (34.70) -215.06 - 408.42   
rs17777002 AA 1056 78.03 (22.63) 76.67 - 79.40 0.945 0.473 
 AG 254 78.15 (22.76) 75.33 - 80.96   
  GG 16 78.11 (25.29) 64.64 - 91.59     
*Adjusted for gender, age, DBP, lnACR, triglycerides, HDL and antihypertensive medication. 
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3.1.4.2 Association of NPHS1 haplotypes with eGFR 
There were no significant associations between NPHS1 haplotypes with eGFR among all 
patients (Table 13). 
 
Table 13. Association of NPHS1 haplotypes with eGFR among all patients. 
Haplotype Freq (%) Mean (se) of eGFR 95%CI P* 
        Specific Global 
T/G/A/T/T/A 33.5 77.13 (0.2) 76.77 - 77.49 0.344 1.000 
T/G/G/C/T/A 15.4 78.58 (1.4) 75.79 - 81.36 0.391  
C/G/A/T/T/A 15.3 78.27 (1.5) 75.41 - 81.14 0.602  
C/A/A/T/T/A 6.7 77.25 (2.0) 73.32 - 81.17 0.766  
T/G/A/T/T/G 5.4 75.84 (2.2) 71.52 - 80.16 0.320   
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3.1.4.3 Interaction of NPHS1 haplotypes with age on eGFR 
Negative slopes of eGFR over age were observed for all haplotypes (Table 14 and Figure 
11). There was significant evidence for interaction of NPHS1 haplotypes with age on 
eGFR. Specifically, with reference to the common T/G/A/T/T/A haplotype, carriers of 
T/G/G/C/T/A had higher eGFR values among younger patients but had lower eGFR 
values among older patients (P= 2.9 x 10
-8
, Pcorrected= 1.7 x 10
-7
). C/A/A/T/T/A carriers 
also reported high eGFR values in younger patients compared to the common haplotype 
(P<0.0001). In contrast, carriers of T/G/A/T/T/G had lower eGFR values among younger 
patients with reference to the common haplotype (P= 1.9 x 10
-5
, Pcorrected= 1.1 x 10
-4
). 
These interactions were still significant after adjusting for possible confounding clinical 










Chapter 3  Results 
49 
 
Table 14. Interaction of NPHS1 haplotypes with age on eGFR. 
Haplotype Freq (%) 
Slope/unit  
Age (yrs) 
95% CI P* 
T/G/A/T/T/A 33.5 -0.86 -0.97;-0.75 (reference) 
T/G/G/C/T/A 15.4 -1.01 -1.13;-0.89 2.9 x 10-8 
C/G/A/T/T/A 15.3 -0.9 -1.02;-0.78 1.8 x 10-1 
C/A/A/T/T/A 6.8 -1.16 -1.29;-1.04 <0.0001 
T/G/A/T/T/G 5.5 -0.72 -0.84;-0.59 1.9 x 10-5 
Rare N/A -0.79 -0.97;-0.61 3.0 x 10-1 
*Adjusted for gender, DBP, HDL, triglycerides, lnACR and antihypertensive medication. 
 
 
Figure 11. Slopes of eGFR over age according to NPHS1 haplotypes. 
Chapter 3  Results 
50 
 
3.1.4.4 Interaction of NPHS1 haplotypes with DM duration on eGFR 
There was no significant haplotype interaction with DM duration on slope of eGFR for 
all haplotypes (Table 15). 
 
Table 15. Interaction of NPHS1 haplotypes with DM duration on eGFR. 
Haplotype Freq (%) 
Slope/unit  
DM duration (yrs) 
95% CI P* 
T/G/A/T/T/A 33.6 0.05 -0.26;0.37 (ref category) 
T/G/G/C/T/A 15.4 -0.26 -0.71;0.19 0.056 
C/G/A/T/T/A 15.3 -0.04 -0.50;0.42 0.580 
C/A/A/T/T/A 6.7 -0.07 -0.62;0.48 0.584 
T/G/A/T/T/G 5.4 -0.30 -0.92;0.32 0.188 
Rare N/A 0.11 -0.29;0.52 0.646 
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3.2 AIM 2 
To investigate the association of NPHS1 SNPs with T2DM-related traits in non-diabetic 
Chinese, Malay and Indian subjects in Singapore. These subjects were from the NHS98 
described in Methods 2.1.2. 
All subjects from the NHS98 were included. This was a cross-sectional study comprising 
of Chinese, Malay and Asian Indian subjects. The subjects were analysed for the 
association of NPHS1 SNPs with T2DM-related traits like BMI, WHR, fasting glucose, 
fasting insulin, HOMA-insulin resistance and HOMA-β-cell function according to 
ethnicity. 
3.2.1 Clinical Characteristics of NHS98 subjects 
There were a total of 2952 Chinese, 792 Malay and 603 Asian Indian subjects (Table 16). 
Among these subjects, Malay and Asian Indian subjects were slightly older and had a 
higher BMI and WHR than the Chinese population. There were slightly fewer males in 
the Chinese subjects while gender composition was similar for the Malay and Indian 
subjects. There was a higher prevalence of T2DM in the Malay and Indian populations. 
The Malay population had higher blood pressure values, total cholesterol, LDL and 
HbA1c% compared to the rest. The Asian Indians had the highest fasting glucose, fasting 
insulin, HOMA-insulin resistance, HOMA-β-cell function followed by the Malay and 
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Table 16. Clinical characteristics of NHS98 subjects stratified by ethnicity. 
 Chinese Malay Asian Indian 
Number (n) 2953 792 603 
Age (years) 37.9 (12.2) 38.9 (12.6) 40.5 (12.0) 
Male gender, n (%) 1342 (45.4) 380 (48.0) 289 (47.9) 
Weight (kg) 60.5 (12.1) 65.7 (13.5) 66.2 (13.0) 
Height (m) 162.8 (8.4) 160.3 (8.6) 162.5 (9.3) 
Body mass index (kg/m
2
) 22.7 (3.7) 25.6 (5.0) 25.1 (4.7) 
Waist-to-hip ratio 0.82 (0.07) 0.83 (0.08) 0.85 (0.08) 
Systolic blood pressure (mmHg) 120.7 (16.4) 124.7 (19.3) 121.2 (17.1) 
Diastolic blood pressure (mmHg) 73.8 (11.3) 76.1 (12.1) 73.6 (12.0) 
Total Cholesterol (mmol/L) 5.42 (1.0) 5.81 (1.2) 5.50 (1.1) 
Triglycerides (mmol/L) 1.40 (1.2) 1.68 (1.3) 1.68 (1.4) 
High density lipoprotein (mmol/L) 1.42 (0.4) 1.30 (0.3) 1.15 (0.3) 
Low density lipoprotein (mmol/L) 3.39 (1.0) 3.86 (1.1) 3.70 (1.0) 
Haemoglobin A1c (%) 8.5 (2.1) 8.9 (2.1) 8.0 (2.0) 
Haemoglobin (mmol/L) 13.9 (1.6) 14.0 (1.7) 13.8 (1.9) 
Fasting Glucose (mmol/L)*^ 5.5 (0 - 17.6) 5.7 (3.5 - 23) 5.8 (4.1 - 19.9) 
Fasting Insulin (mU/L)*^ 6.1 (0.2 - 53.3) 7.2 (0.7 - 83.4) 8.6 (1 - 119) 
HOMA Insulin resistance*^ 1.48 (0 - 11.9) 1.84 (0.1 - 22.2) 2.19 (0.2 - 31.2) 
HOMA β-cell function (%)*^ 64.2 (2.1 - 761.4) 69.3 (2.8 - 667.2) 80.7  (6.1 - 991.7) 
Diabetes medication, n  59 35 42 
    
Glucose tolerance, n (%)    
   NGT 2205 (74.7) 475 (60.0) 367 (60.9) 
   IFG 162 (5.5) 60 (7.6) 36 (6.0) 
   IGT 360 (12.2) 143 (18.0) 84 (13.9) 
   T2DM 225 (7.6) 114 (14.4) 116 (19.2) 
    *Geometric mean (range) shown due to skewed nature of data; ^Subjects taking diabetes 
medication were excluded (59 Chinese, 35 Malays and 42 Asian Indians); NGT, normal glucose 
tolerance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; T2DM, type 2 
diabetes mellitus. 
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3.2.2 HWE and LD of NPHS1 SNPs in NHS98 subjects 
Genotype data from 4348 subjects from NHS98 were available at the time of this study. 
Genotype distributions of all six SNPs were in HWE across all ethnic groups 
(Supplementary Table 6). LD was low for all SNPs in all populations and displayed 
similar trends for all races (Supplementary Table 7). 
3.2.3 NPHS1 and T2DM-related traits 
3.2.3.1 Association of NPHS1 SNPs with T2DM-related traits in all subjects 
The risk allele for SNP rs437168 was associated with a lower WHR among Chinese and 
was able to withstand Bonferroni correction (P=0.004, Pcorrected=0.024) (Table 17). This 
association became stronger after analysis was restricted to include only non-diabetic 
subjects (P=0.002, Pcorrected=0.012) (Supplementary Table 8). On the other hand, the 
Malays and Asian Indians reported a higher WHR as number of risk alleles increased but 
the association failed to reach statistical significance.   
There was an association of risk allele for SNP rs17777002 with higher WHR in the 
Asian Indian population (P=0.005, Pcorrected=0.030) (Table 17). This association remained 
significant with the exclusion of diabetic subjects (P=0.003, Pcorrected=0.018) 
(Supplementary Table 8).  
SNPs rs3814995, rs10409299, rs2071327 and rs460560 did not appear to have any 
associations with any of the T2DM-related traits in all races that could withstand 
correction for multiple comparisons. 
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Number of risk alleles 0 1 2 0 1 2 0 1 2 
             
rs3814995 (T>C)             
BMI (kg/m2) 22.9 22.7 22.4 0.011 25.7 25.6 25.5 0.626 24.2 24.8 25.4 0.030 
WHR 0.826 0.824 0.821 0.092 0.832 0.833 0.834 0.723 0.843 0.852 0.860 0.022 
Fasting glucose (mmol/l)
†
^ 5.4 5.5 5.5 0.299 5.7 5.7 5.7 0.634 5.7 5.7 5.8 0.414 
Fasting insulin (mmol/l)
†
^ 6.1 6.1 6.1 0.878 7.3 7.3 7.2 0.748 8.8 8.7 8.6 0.633 
HOMA-insulin resistance
†
^ 1.5 1.5 1.5 0.983 1.9 1.8 1.8 0.906 2.2 2.2 2.2 0.811 
HOMA-β-cell function (%)
†
^# 65.0 64.3 63.6 0.315 70.7 69.9 69.1 0.632 84.9 82.6 80.4 0.367 
             
rs437168 (G>A)             
BMI (kg/m2) 22.8 22.6 22.5 0.265 25.5 26.1 26.7 0.096 25.1 25.3 25.5 0.669 
WHR 0.826 0.821 0.815 0.004 0.831 0.838 0.845 0.089 0.856 0.858 0.860 0.738 
Fasting glucose (mmol/l)
†
^ 5.5 5.5 5.5 0.709 5.7 5.7 5.7 0.844 5.8 5.7 5.5 0.278 
Fasting insulin (mmol/l)
†
^ 6.1 6.0 5.9 0.215 7.3 7.0 6.8 0.405 8.8 8.0 7.3 0.119 
HOMA-insulin resistance
†
^ 1.5 1.5 1.4 0.253 1.9 1.8 1.7 0.468 2.2 2.0 1.8 0.068 
HOMA-β-cell function (%)
†
^# 64.5 64 63.5 0.579 70.2 69.3 68.4 0.741 81.8 80.7 79.6 0.792 
             
rs10409299 (A>G)             
BMI (kg/m2) 22.7 22.7 22.7 0.747 25.7 25.5 25.3 0.414 25.4 25.2 25.3 0.781 
WHR 0.824 0.824 0.825 0.626 0.832 0.833 0.834 0.781 0.856 0.854 0.851 0.489 
Fasting glucose (mmol/l)
†
^ 5.4 5.5 5.5 0.196 5.7 5.7 5.6 0.491 5.8 5.7 5.6 0.316 
Fasting insulin (mmol/l)
†
^ 6.0 6.1 6.3 0.188 7.1 7.4 7.7 0.167 8.7 8.6 8.5 0.763 
HOMA-insulin resistance
†
^ 1.5 1.5 1.5 0.131 1.8 1.9 1.9 0.329 2.2 2.2 2.1 0.588 
HOMA-β-cell function (%)
†
^# 64.5 64.0 63.6 0.537 68.7 71.2 73.8 0.200 81.7 82.7 83.7 0.721 
             
rs2071327 (T>C)             
BMI (kg/m2) 22.7 22.7 22.7 0.973 25.8 25.5 25.2 0.266 25.3 25.1 24.9 0.504 
WHR 0.824 0.824 0.825 0.706 0.834 0.831 0.828 0.314 0.855 0.855 0.856 0.826 
Fasting glucose (mmol/l)
†
^ 5.5 5.5 5.5 0.609 5.8 5.7 5.6 0.129 5.7 5.8 5.8 0.542 
Fasting insulin (mmol/l)
†
^ 6.1 6.1 6.2 0.354 7.2 7.3 7.3 0.765 8.8 8.6 8.5 0.476 
HOMA-insulin resistance
†
^ 1.5 1.5 1.5 0.342 1.8 1.8 1.8 0.898 2.2 2.2 2.2 0.689 
HOMA-β-cell function (%)
†
^# 64.5 64.5 64.4 0.929 68.1 70.7 73.5 0.138 84.2 81.7 79.2 0.276 
             
rs460560 (T>C)             
BMI (kg/m2) 22.7 22.7 22.7 0.988 25.5 26.2 26.9 0.172 25.2 24.9 24.6 0.365 
WHR 0.824 0.823 0.822 0.590 0.833 0.835 0.836 0.754 0.857 0.853 0.848 0.334 
Fasting glucose (mmol/l)
†
^ 5.5 5.4 5.4 0.488 5.7 5.6 5.4 0.101 5.8 5.8 5.8 0.934 
Fasting insulin (mmol/l)
†
^ 6.1 6.0 5.9 0.386 7.3 7.0 6.8 0.587 8.8 8.4 8.1 0.257 
HOMA-insulin resistance
†
^ 1.5 1.4 1.4 0.329 1.8 1.7 1.6 0.344 2.2 2.1 2.0 0.280 
HOMA-β-cell function (%)
†
^# 64.3 64.7 65.1 0.746 69.3 74.4 80.0 0.152 82.6 81.4 80.3 0.689 
             
rs17777002 (A>G)             
BMI (kg/m2) 22.7 22.9 23.2 0.072 25.6 25.7 25.9 0.751 25.0 25.3 25.6 0.360 
WHR 0.824 0.824 0.824 0.922 0.832 0.835 0.838 0.549 0.850 0.863 0.875 0.005 
Fasting glucose (mmol/l)
†
^ 5.5 5.5 5.5 0.797 5.7 5.7 5.7 0.888 5.7 5.8 6.0 0.174 
Fasting insulin (mmol/l)
†
^ 6.1 6.1 6.1 0.791 7.3 7.1 7.0 0.721 8.7 8.5 8.4 0.701 
HOMA-insulin resistance
†
^ 1.5 1.5 1.5 0.740 1.8 1.8 1.8 0.790 2.2 2.2 2.2 0.813 
HOMA-β-cell function (%)
†
^# 64.4 64.7 64.9 0.805 70.2 70.5 70.9 0.917 83 78.9 75.1 0.177 
             
*All analyses were gender and age adjusted; 
†
values were natural log transformed to improve normality in 
regression analysis, and adjusted means were subsequently back transformed; ^additionally adjusted for 
BMI and excluding subjects taking diabetic medication (59 Chinese, 35 Malays and 42 Asian Indians); 
#
additionally adjusted for insulin resistance; bold-faced P-values are <0.05 after Bonferroni correction. 
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3.3 AIM 3 
To investigate the association of NPHS1 SNPs with T2DM in Chinese subjects in 
Singapore. Cases with T2DM were from both SDCS and NHS98 (Methods 2.1.1 and 
2.1.2) and non-diabetic controls were from NHS98 (Methods 2.1.2). 
The number of T2DM cases in NHS98 was relatively limited. Hence by taking in 
Chinese cases from SDCS, a larger case-control study for T2DM could be conducted for 
the Chinese population. This formed a case-control study where cases were T2DM 
patients from both SDCS and NHS98, and controls were NGT and IFG/IGT subjects 
from NHS98. The association of single NPHS1 SNPs and haplotypes with T2DM was 
examined and the odds ratios were reported. 
3.3.1 Clinical characteristics of Chinese SDCS and NHS98 subjects 
Patients were grouped according to their glucose tolerance status. Subjects with NGT 
were controls while individuals with IFG/IGT and T2DM were cases. Controls had 
slightly fewer males compared to cases (Table 18). Cases were much older than controls 
and had higher BMI, WHR, SBP and DBP values. In addition, the proportion of subjects 
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Table 18. Clinical characteristics of Chinese patients from NHS98 and SDCS stratified by 
glucose tolerance status. 
 NGT IFG/IGT T2DM P 
Number (n) 2205 522 1588  
Age (years) 35.3 (11.2) 43.2 (11.4) 62.1 (11.0) <0.0001 
Male gender, n (%) 969 (43.9) 263 (50.4) 786 (49.5) 0.002 
Body mass index (kg/m
2
) 22.1 (3.4) 24.3 (3.6) 25.4 (3.9) <0.0001 
Waist-to-hip ratio 0.81 (0.07) 0.85 (0.07) 0.90 (0.07) <0.0001 
Systolic blood pressure (mmHg) 117.5 (13.8) 127.4 (17.3) 134.6 (14.2) <0.0001 
Diastolic blood pressure (mmHg) 71.8 (10.5) 78.5 (10.9) 78.0 (8.6) <0.0001 
Total cholesterol (mmol/L) 5.3 (1.0) 5.8 (1.1) 4.9 (1.0) <0.0001 
Triglyceride (mmol/L) 1.2 (0.8) 1.8 (1.4) 1.6 (1.2) <0.0001 
High density lipoprotein (mmol/L) 1.5 (0.4) 1.3 (0.4) 1.3 (0.3) <0.0001 
Low density lipoprotein (mmol/L) 3.2 (0.9) 3.7 (1.0) 3.0 (0.8) <0.0001 
Haemoglobin A1C (%) NA NA 7.4 (1.1) NA 
Diabetes duration (years) 0 0 6 (2-14) <0.0001 
Diabetes medication, n 0 0 1110 <0.0001 
Antihypertensive medication (Y/N) 79/2126 56/466 1198/371 <0.0001 
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3.3.2 HWE of NPHS1 SNPs in Chinese SDCS and NHS98 subjects 
All SNPs did not deviate from HWE among subjects grouped according to glucose 
tolerance status except for SNP rs3814995 of the NGT group (P=0.0002) (Supplementary 
Table 9). It had a slight excess of heterozygotes than expected but due to the large sample 
size of the NGT group, it became significant. However, SNP rs3814995 was retained in 
the analysis for completeness. 
3.3.3 NPHS1 and glucose tolerance status in Chinese 
3.3.3.1 Association of NPHS1 SNPs with IGT/IFG and T2DM in Chinese 
In the additive model, there was no significant association of any NPHS1 variants with 
IGT/IFG and T2DM (Table 19). Similarly, the dominant and recessive models did not 
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(2) vs (1) 
P* 
(3) vs (1) 
P* 
OR (95% CI) OR (95% CI) 
rs3814995 TT 810 (37.7) 210 (41.8) 595 (38.4)         
(T>C) CT 1084 (50.4) 233 (46.3) 711 (45.9) 0.94 (0.80-1.11) 0.460 1.05 (0.86-1.28) 0.632 
 CC 256 (11.9) 60 (11.9) 243 (15.7)     
rs437168 GG 1548 (71.9) 380 (75.7) 1132 (71.9)     
(G>A) AG 556 (25.8) 107 (21.3) 396 (25.1) 0.94 (0.76-1.16) 0.538 1.17 (0.90-1.53) 0.240 
 AA 49 (2.3) 15 (3.0) 47 (3.0)     
rs10409299 AA 1204 (55.7) 290 (57.5) 847 (54.9)     
(A>G) AG 822 (38.0) 184 (36.5) 594 (38.5) 0.93 (0.78-1.10) 0.390 1.07 (0.86-1.33) 0.567 
 GG 135 (6.3) 30 (6.0) 103 (6.7)     
rs2071327 TT 921 (42.8) 210 (42.2) 631 (40.7)     
(T>C) CT 948 (44.1) 216 (43.4) 724 (46.7) 1.03 (0.86-1.21) 0.680 0.99 (0.81-1.21) 0.949 
 CC 283 (13.1) 72 (14.4) 195 (12.6)     
rs460560 TT 1895 (86.8) 436 (85.2) 1377 (88.1)     
(T>C) CT 279 (12.8) 74 (14.4) 185 (11.8) 1.17(0.88-1.56) 0.283 0.80 (0.54-1.19) 0.268 
 CC 9 (0.4) 2 (0.4) 2 (0.1)     
rs17777002 AA 1667 (76.7) 368 (72.3) 1228 (79.1)     
(A>G) AG 469 (21.6) 135 (26.5) 305 (19.7) 1.16 (0.94-1.45) 0.168 0.95 (0.71-1.26) 0.700 
  GG 36 (1.7) 6 (1.2) 19 (1.2)         
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3.3.3.2 Association of NPHS1 haplotypes with IGT/IFG and T2DM in Chinese 
With reference to the most common haplotype, none of the remaining haplotypes were 
significantly associated with IGT/IFG or T2DM after correction (Table 20). 
 
Table 20. Association of NPHS1 haplotypes with T2DM among Chinese. 
    (2) vs (1) (3) vs (1) 










95%CI Specific Global Specific Global 
T/G/A/T/C/G 32.9 31-34.9 31.6 27.6-35.8 33.1 30.8-35.5 0.483 0.699 0.959 0.412 
T/G/G/C/T/A 14.8 13.3-16.3 13.6 10.8-16.8 15.6 13.9-17.5 0.334  0.774  
C/G/A/T/T/A 13.0 11.7-14.5 11.3 8.7-14.3 14.5 12.8-16.3 0.438  0.715  
T/G/A/T/T/G 5.9 4.9-7 8.5 6.2-11.2 7.0 5.8-8.4 0.034  0.588  
C/A/A/T/T/A 6.3 5.4-7.4 6.0 4.1-8.3 5.4 4.3-6.6 0.752  0.021  
Total 72.9  71.0  75.6      
*Adjusted for age, gender, BMI, WHR, SBP, DBP cholesterol, triglycerides, LDL, HDL and 
antihypertensive medication.
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CHAPTER 4: DISCUSSION 
4.1 Discussion of results 
In our study, we investigated whether common genetic variations of NPHS1 were 
associated with renal and T2DM-related traits. 
We did not find any association of individual NPHS1 SNPs and haplotypes with 
albuminuria and eGFR in the Chinese population. Previous studies investigating effects 
of individual NPHS1 common genetic variations in Caucasian diabetic patients also 
reported a lack of NPHS1 genetic involvement in DN [75-77]. Even though our study had 
a larger sample size, associations did not surface. This could be a reflection of true 
negative results in the local Chinese population. Despite this, the potential for NPHS1 
haplotype interactions with patient characteristics on renal traits were not overlooked. 
Our most significant finding suggested that NPHS1 haplotypes interacted significantly 
with age on eGFR. This was consistent with the predominant view that NPHS1 plays an 
important role in the kidney [40-48]. On the other hand, haplotypes did not interact with 
DM duration on eGFR. This may potentially be related to the fact that DM duration, 
unlike age, is not precisely known since many patients escape T2DM diagnosis for 
several years. Therefore, an underlying interaction of haplotypes with DM duration on 
eGFR may be harder to observe. Interestingly, although NPHS1 was initially implicated 
in the massive proteinuria in CNF, genetic variation in NPHS1 was not associated with 
albuminuria, but only with eGFR. However, this eGFR association was in line with 
previous observations that nephrinuria was associated with renal function [73, 74]. 
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Common genetic variations and haplotypes of NPHS1 were not associated with T2DM 
and its related traits. This finding varied from that reported in the Japanese where a SNP 
rs437168 common to our study was significantly associated with T2DM [80]. We did not 
find a similar association in our Chinese population. This could be attributed to 
population specific genetic differences or a limited sample size of the Funagata Study. 
Nonetheless, our negative findings indirectly corroborated with the findings on 
albuminuria in the Caucasian study on T1 and T2DM subjects although they had studied 
a different set of SNPs [77].  
There was some indication of the association of NPHS1 common genetic variations with 
WHR after correction, although the biological plausibility is less well understood. This 
association was novel, the first reported to our knowledge. Although its statistical 
significance was not very strong, especially after correction, this finding clearly needs to 
be replicated in other populations. Indeed, in view of the studies implicating NPHS1 in β-
cell function, this association with WHR is unexpected and its biological basis is not 
obvious. On the other hand, our results do strongly suggest that NPHS1 does not 
modulate susceptibility to β-cell dysfunction. 
Despite the positive findings, a few limitations of our study should be acknowledged. 
Firstly, this study is cross-sectional, hence conclusions regarding the change of eGFR 
over age is limited. Ideally, this finding should be replicated in a cohort study where 
changes of eGFR over time in individual patients can be monitored. Secondly, renal 
function was not directly measured but was estimated using the widely used MDRD 
formula. This was necessarily so, as obtaining direct GFR measurements are invasive and 
logistically difficult to carry out in such large numbers of patients. Thirdly, we cannot 
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exclude the possibility that reduced renal function and albuminuria may have a non-
diabetic origin. However, previous studies in T2DM patients suggest that non-diabetic 
renal disease in T2DM patients is relatively uncommon [85]. Fourthly, our analysis 
cannot be readily extrapolated to the non-Chinese ethnicities because our analysis was 
confined to the Chinese patients at the time of our study as the number of Malays and 
Asian Indians from the NHS98 was relatively smaller compared to their Chinese 
counterparts. 
On balance, our study does have a few strengths. Firstly, our positive findings were 
highly significant. This was evidenced by small P-values which remained significant 
after correction. This gave us some measures of confidence that our findings were true 
positives although replications in other independent populations are needed to confirm 
their validity. Secondly, our study was conducted in a substantial number of people 
especially in the Chinese ethnicity. This was made possible by leveraging on the existing 
cohort of SDCS and NHS98. Thirdly, our study surveyed the common genetic variations 
across the entire NPHS1 gene. This approach extended beyond that of the previously 
reported studies which had focused on only a few SNPs. Our analysis was also 
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4.2 Further studies 
4.2.1 Follow-up studies 
Given that the SDCS was started in 2004, one intriguing study that can be performed 
would be to assess whether these common genetic variations of NPHS1 have associations 
with renal function and albuminuria from baseline until the present moment. In this 
regard, we would be able to assess these changes of parameters over time, instead of 
talking about slopes of eGFR over age or DM duration. 
4.2.2 Candidate genes 
Current genome wide association study efforts to identify genes associated with DN have 
met with limited success. As such, it might be possible to identify new susceptible genes 
using the candidate gene approach. In this respect, the proteins that interact with NPHS1 
at the SD have been well characterised and can be studied. 
Our study suggests that NPHS1 haplotypes may modulate renal function over time. To 
extend this finding, it may be possible to investigate if rare genetic variants of NPHS1 
may play even stronger roles in modulating these traits. Such a study can be performed 
using next generation sequencing although the cost of studying many patient samples 
may still be prohibitive. 
4.2.3 Molecular characterisation of NPHS1 
Urinary NPHS1 could be measured in T2DM patients using commercially available 
ELISA kits. With this additional data made available, the association of nephrinuria with 
common genetic variations of NPHS1 could be further investigated. Intuitively, urinary 
NPHS1 should arise as a result of glomerular damage due to DN and may not be closely 
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linked to T2DM and its related traits as NPHS1 from the β-cells are potentially unlikely 
to surface in the urine.  
A previous study reported that podocyte-specific deletion of insulin receptors in mice 
resulted in albuminuria along with histological features typical of DN. Thus, there may 
be an interesting relationship between insulin signaling and nephrinuria and vice versa 
[86, 87]. In addition, insulin was found to influence the in vitro actin reorganisation of 
human podocytes resulting in higher permeability of foot processes [87]. Therefore, the 
association of insulin signaling with nephrinuria could be a potential area for future 
research.  
4.3 Conclusion 
Our investigation has uncovered first evidence that NPHS1 may be potentially involved 
in the modulation of eGFR over time in patients with T2DM. This may have significant 
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rs3814995 0.392 0.752 
rs437168 0.153 0.534 
rs10409299 0.257 0.774 
rs2071327 0.359 0.623 
rs460560 0.061 0.231 
rs17777002 0.108 0.940 
 
 
Supplementary Table 2. HWE of NPHS1 SNPs in SDCS patients stratified by albuminuric 
status. 
SNP  Genotype CTRLS MICRO MACRO 
  N PHWE N PHWE N PHWE 
rs3814995 TT 311 0.600 126 0.894 34 0.684 
(T>C) CT 399  159  47  
 CC 140  47  12  
rs437168 GG 613 0.736 244 0.826 72 0.408 
(G>A) AG 225  86  19  
 AA 25  7  3  
rs10409299 AA 469 0.870 189 0.695 50 1.000 
(A>G) AG 321  117  37  
 GG 57  21  7  
rs2071327 TT 340 0.813 144 0.374 39 1.000 
(T>C) CT 387  157  44  
 CC 115  33  11  
rs460560 TT 746 0.556 0 0.741 0 1.000 
(T>C) CT 108  36  8  
 CC 2  299  85  
rs17777002 AA 671 0.873 267 0.625 76 0.895 
(A>G) AG 167  61  17  





Supplementary Table 3. LD of NPHS1 SNPs in SDCS patients indicated by D’ (top right 
triangle) and r
2
 (bottom left triangle) values. 
SNP rs3814995 rs437168 rs10409299 rs2071327 rs460560 rs17777002 
rs3814995 1.000 0.989 0.050 0.009 0.019 0.132 
rs437168 0.273 1.000 0.109 0.132 0.594 0.144 
rs10409299 0.001 0.006 1.000 0.982 1.000 0.391 
rs2071327 0.000 0.006 0.605 1.000 1.000 0.499 
rs460560 0.000 0.004 0.023 0.117 1.000 1.000 




Supplementary Table 4. Association of NPHS1 SNPs with stages of DN (dominant model). 







(2) vs (1) 
P* 
(3) vs (1) 
P* 
OR (95% CI) OR (95% CI) 
         
rs3814995 TT 311 (36.6) 126 (38.0) 34 (36.6)     
 CT/CC 539 (63.4) 206 (62.0) 59 (63.4) 0.98 (0.79-1.31) 0.890 1.09 (0.64-1.87) 0.741 
rs437168 GG 613 (71.0) 244 (72.4) 72 (76.6)     
 AG/AA 250 (29.0) 93 (27.6) 22 (23.4) 0.81 (0.58-1.11) 0.188 0.65 (0.35-1.19) 0.161 
rs10409299 AA 469 (55.4) 189 (57.8) 50 (53.2)     
 AG/GG 378 (44.6) 138 (42.2) 44 (46.8) 0.92 (0.69-1.23) 0.589 1.20 (0.72-2.00) 0.473 
rs2071327 TT 340 (40.4) 144 (43.1) 39 (41.5)     
 CT/CC 502 (59.6) 190 (56.9) 55 (58.5) 0.89 (0.66-1.18) 0.405 1.05 (0.62-1.77) 0.857 
rs460560 TT 746 (87.1) 299 (89.3) 85 (91.4)     
 CT/CC 110 (12.9) 36 (10.7) 8 (8.6) 0.84 (0.54-1.29) 0.419 0.60 (0.24-1.47) 0.261 
rs17777002 AA 671 (79.2) 267 (80.2) 76 (81.7)     
 AG/GG 176 (20.8) 66 (19.8) 17 (18.3) 0.93 (0.65-1.32) 0.687 0.84 (0.44-1.61) 0.599 
         
*Adjusted for age, WHR, DM duration, HbA1C%, SBP, triglycerides, cholesterol, LDL, eGFR, 







Supplementary Table 5. Association of NPHS1 SNPs with stages of DN (recessive model). 





(2) vs (1) 
P* 
(3) vs (1) 
P* 
OR (95% CI) OR (95% CI) 
         
rs3814995 TT/CT 710 (83.5) 285 (85.8) 81 (87.1) 0.86 (0.57-1.28) 0.455 0.76 (0.36-1.62) 0.482 
 CC 140 (16.5) 47 (14.2) 12 (12.9)     
rs437168 GG/AG 838 (97.1) 330 (97.9) 91 (96.8) 0.63 (0.23-1.72) 0.372 0.83 (0.15-4.65) 0.831 
 AA 25 (2.9) 7 (2.1) 3 (3.2)     
rs10409299 AA/AG 790 (93.3) 306 (93.6) 87 (92.6) 1.07 (0.60-1.91) 0.824 1.27 (0.48-3.35) 0.623 
 GG 57 (6.7) 21 (6.4) 7 (7.4)     
rs2071327 TT/CT 727 (86.3) 301 (90.1) 83 (88.3) 0.73 (0.46-1.16) 0.184 0.74 (0.32-1.70) 0.482 
 CC 115 (16.7) 33 (9.9) 11 (11.7)     
rs460560 TT/CT 854 (99.8) 335 (100) 93 (100) NA NA NA NA 
 CC 2 (0.2) 0 (0) 0 (0)     
rs17777002 AA/AG 838 (98.9) 328 (98.5) 93 (100) 1.17 (0.35-3.97) 0.798 NA NA 
 GG 9 (1.1) 5 (1.5) 0 (0)     
         
*Adjusted for age, WHR, DM duration, HbA1C%, SBP, triglycerides, cholesterol, LDL, eGFR, 
antihypertensive medication and diabetes medication. 
 
 
Supplementary Table 6. HWE of NPHS1 SNPs in NHS98 subjects stratified by ethnicity. 
SNP 
Chinese Malay Asian Indian 
MAF PHWE MAF PHWE MAF PHWE 
rs3814995 0.366 0.006 0.473 0.659 0.284 0.165 
rs437168 0.149 0.382 0.110 0.415 0.085 1.000 
rs10409299 0.253 0.625 0.268 0.688 0.215 1.000 
rs2071327 0.355 0.066 0.351 0.787 0.484 0.905 
rs460560 0.069 0.526 0.064 0.733 0.190 0.471 








Supplementary Table 7. LD of NPHS1 SNPs in NHS98 subjects stratified by ethnicity 






SNP rs3814995 rs437168 rs10409299 rs2071327 rs460560 rs17777002 
rs3814995 1.000 0.933 0.044 0.011 0.044 0.124 
rs437168 0.260 1.000 0.067 0.128 0.172 0.088 
rs10409299 0.000 0.002 1.000 0.842 0.500 0.344 
rs2071327 0.000 0.005 0.437 1.000 0.968 0.462 
rs460560 0.000 0.000 0.006 0.128 1.000 0.875 






SNP rs3814995 rs437168 rs10409299 rs2071327 rs460560 rs17777002 
rs3814995 1.000 0.886 0.239 0.128 0.284 0.004 
rs437168 0.107 1.000 0.354 0.024 0.289 0.082 
rs10409299 0.019 0.006 1.000 0.775 0.514 0.384 
rs2071327 0.008 0.000 0.410 1.000 0.858 0.042 
rs460560 0.006 0.001 0.007 0.096 1.000 0.007 











SNP rs3814995 rs437168 rs10409299 rs2071327 rs460560 rs17777002 
rs3814995 1.000 0.751 0.167 0.248 0.241 0.121 
rs437168 0.020 1.000 0.093 0.063 0.040 0.151 
rs10409299 0.003 0.000 1.000 0.791 0.933 0.616 
rs2071327 0.025 0.000 0.161 1.000 0.942 0.198 
rs460560 0.005 0.001 0.058 0.198 1.000 0.493 













Supplementary Table 8. Association of NPHS1 SNPs with T2DM-related traits in NHS98 subjects 







Number of risk alleles 0 1 2 0 1 2 0 1 2 
             
rs3814995 (T>C)             
BMI (kg/m2) 22.6 22.4 22.2 0.035 25.3 25.1 24.9 0.470 23.9 24.4 24.9 0.107 
WHR 0.821 0.818 0.815 0.077 0.825 0.825 0.824 0.803 0.836 0.84 0.844 0.280 
Fasting glucose (mmol/l)
†
^ 5.3 5.4 5.4 0.200 5.5 5.5 5.5 0.748 5.5 5.4 5.4 0.816 
Fasting insulin (mmol/l)
†
^ 5.9 6.0 6.0 0.775 7.0 6.9 6.8 0.763 8.3 8.2 8.1 0.718 
HOMA-insulin resistance
†
^ 1.4 1.4 1.4 0.650 1.7 1.7 1.7 0.817 2.0 2.0 2.0 0.708 
HOMA-β-cell function (%)
†
^# 66.0 65.2 64.4 0.171 72.7 72.0 71.4 0.617 86.0 86.0 86.0 0.995 
             
rs437168 (G>A)             
BMI (kg/m2) 22.5 22.4 22.3 0.324 25 25.4 25.9 0.251 24.6 24.7 24.8 0.878 
WHR 0.820 0.815 0.809 0.002 0.822 0.830 0.838 0.077 0.842 0.841 0.840 0.852 
Fasting glucose (mmol/l)
†
^ 5.4 5.4 5.4 0.984 5.5 5.5 5.5 0.473 5.5 5.4 5.4 0.521 
Fasting insulin (mmol/l)
†
^ 6.0 5.9 5.7 0.233 6.9 6.8 6.7 0.665 8.3 7.6 6.9 0.121 
HOMA-insulin resistance
†
^ 1.4 1.4 1.4 0.254 1.7 1.7 1.6 0.771 2.0 1.8 1.7 0.119 
HOMA-β-cell function (%)
†
^# 65.5 65.1 64.6 0.542 72.4 70.9 69.5 0.483 86.2 85.6 84.9 0.827 
             
rs10409299 (A>G)             
BMI (kg/m2) 22.5 22.5 22.5 0.910 25.2 25 24.7 0.344 24.7 24.6 24.6 0.841 
WHR 0.818 0.819 0.821 0.374 0.823 0.826 0.829 0.381 0.843 0.839 0.835 0.322 
Fasting glucose (mmol/l)
†
^ 5.4 5.4 5.4 0.544 5.5 5.5 5.5 0.759 5.4 5.4 5.5 0.820 
Fasting insulin (mmol/l)
†
^ 5.9 6.0 6.1 0.180 6.7 7.1 7.5 0.085 8.3 8.2 8.1 0.768 
HOMA-insulin resistance
†
^ 1.4 1.4 1.5 0.166 1.6 1.7 1.8 0.092 2.0 2.0 2.0 0.808 
HOMA-β-cell function (%)
†
^# 65.7 65.5 65.3 0.785 71.9 72.6 73.2 0.663 87.1 86.4 85.8 0.724 
             
rs2071327 (T>C)             
BMI (kg/m2) 22.5 22.5 22.5 0.730 25.3 25 24.6 0.209 24.7 24.7 24.6 0.785 
WHR 0.818 0.819 0.82 0.582 0.824 0.823 0.823 0.878 0.844 0.841 0.839 0.551 
Fasting glucose (mmol/l)
†
^ 5.4 5.4 5.4 0.592 5.5 5.5 5.5 1.000 5.5 5.4 5.4 0.787 
Fasting insulin (mmol/l)
†
^ 5.9 6.0 6.1 0.371 6.7 6.9 7.2 0.218 8.4 8.2 8.0 0.419 
HOMA-insulin resistance
†
^ 1.4 1.4 1.4 0.347 1.6 1.7 1.8 0.242 2.0 2.0 1.9 0.423 
HOMA-β-cell function (%)
†
^# 65.7 65.5 65.3 0.711 71.7 72.1 72.6 0.758 85.8 86.1 86.3 0.868 
             
rs460560 (T>C)             
BMI (kg/m2) 22.5 22.5 22.5 0.973 25.1 25.4 25.8 0.461 24.8 24.4 24 0.241 
WHR 0.819 0.817 0.816 0.579 0.825 0.825 0.826 0.923 0.843 0.837 0.832 0.180 
Fasting glucose (mmol/l)
†
^ 5.4 5.4 5.4 0.835 5.5 5.4 5.3 0.196 5.4 5.4 5.4 0.905 
Fasting insulin (mmol/l)
†
^ 6.0 5.8 5.7 0.383 6.9 7.0 7.2 0.709 8.3 8.1 7.9 0.466 
HOMA-insulin resistance
†
^ 1.4 1.4 1.4 0.385 1.7 1.7 1.7 0.892 2.0 2.0 1.9 0.504 
HOMA-β-cell function (%)
†
^# 65.3 65.3 65.2 0.935 71.6 74.9 78.3 0.233 86.9 86.3 85.7 0.763 
             
rs17777002 (A>G)             
BMI (kg/m2) 22.4 22.7 23 0.034 25.1 25.1 23.1 0.982 24.5 24.9 25.3 0.320 
WHR 0.818 0.819 0.82 0.612 0.824 0.826 0.828 0.716 0.836 0.850 0.864 0.003 
Fasting glucose (mmol/l)†^ 5.4 5.4 5.4 0.668 5.5 5.4 5.3 0.092 5.5 5.4 5.4 0.266 
Fasting insulin (mmol/l)†^ 6.0 6.0 5.9 0.892 6.9 7.0 7.1 0.789 8.2 8.2 8.3 0.827 
HOMA-insulin resistance†^ 1.4 1.4 1.4 0.943 1.7 1.7 1.7 0.971 2.0 2.0 2.0 0.969 
HOMA-β-cell function (%)†^# 65.5 65.3 65.1 0.790 71.6 76.9 82.6 0.048 85.0 87.8 90.7 0.187 
             
T2DM subjects were excluded from analyses; *all analyses were gender and age adjusted; †values were natural log 
transformed to improve normality in regression analysis, and adjusted means were subsequently back transformed; 
^additionally adjusted for BMI and excluding subjects taking diabetic medication (59 Chinese, 35 Malays and 42 Asian 




Supplementary Table 9. HWE test for NPHS1 SNPs in Chinese SDCS and NHS98 subjects 
stratified by glucose tolerance status. 
SNP  NGT IGT/IFG T2DM 
 Genotype N PHWE N PHWE N PHWE 
rs3814995 TT 810 0.0002 210 0.798 595 0.238 
(T>C) CT 1084  233  711  
 CC 256  60  243  
rs437168 GG 1548 0.997 380 0.096 1132 0.338 
(G>A) AG 556  107  386  
 AA 49  15  47  
rs10409299 AA 1204 0.786 290 1.000 847 1.000 
(A>G) AG 822  184  594  
 GG 135  30  103  
rs2071327 TT 921 0.123 210 0.203 631 0.589 
(T>C) CT 948  216  724  
 CC 283  72  195  
rs460560 TT 1895 0.875 436 0.840 1377 0.132 
(T>C) CT 279  74  185  
 CC 9  2  2  
rs17777002 AA 1667 0.821 368 0.067 1228 1.000 
(A>G) AG 469  135  305  



















Supplementary Table 10. Association of NPHS1 SNPs with T2DM among Chinese 
(dominant model). 







(2) vs (1) 
P* 
(3) vs (1) 
P* 
OR (95% CI) OR (95% CI) 
rs3814995 TT 810 (37.7) 210 (41.8) 595 (38.4)     
 CT/CC 1340 (62.3) 293 (58.2) 954 (61.6) 0.89 (0.72-1.10) 0.284 0.91 (0.69-1.20) 0.503 
         
rs437168 GG 1548 (71.9) 380 (75.7) 1132 (71.9)     
 AG/AA 605 (28.1) 122 (24.3) 443 (28.1) 0.87 (0.68-1.11) 0.261 1.12 (0.83-1.51) 0.467 
         
rs10409299 AA 1204 (55.7) 290 (57.5) 847 (54.9)     
 AG/GG 957 (44.3) 214 (42.5) 697 (45.1) 0.90 (0.73-1.12) 0.356 1.10 (0.84-1.44) 0.487 
         
rs2071327 TT 921 (42.8) 210 (42.2) 631 (40.7)     
 CT/CC 1231 (57.2) 288 (57.8) 919 (59.3) 0.99 (0.80-1.23) 0.956 1.03 (0.79-1.36) 0.807 
         
rs460560 TT 1895 (86.8) 436 (85.2) 1377 (88.0)     
 CT/CC 288 (13.2) 76 (14.8) 187 (12.0) 1.17 (0.87-1.57) 0.311 0.82 (0.55-1.22) 0.330 
         
rs17777002 AA 1667 (76.8) 368 (72.3) 1228 (79.1)     
 AG/GG 505 (23.2) 141 (27.7) 324 (20.9) 1.26 (0.99-1.60) 0.056 0.97 (0.71-1.33) 0.855 
                  





















Supplementary Table 11. Association of NPHS1 SNPs with T2DM among Chinese 
(recessive model) 
SNP   NGT (1) IGT/IFG (2) T2DM (3) 
(2) vs (1) 
P* 
(3) vs (1) 
P* 
OR (95% CI) OR (95% CI) 
rs3814995 TT/CT 1894 (88.1) 443 (88.1) 1306 (84.3)     
 CC 256 (11.9) 60 (11.9) 243 (15.7) 1.02 (0.73-1.41) 0.910 1.47 (0.99-2.20) 0.054 
         
rs437168 GG/AG 2104 (97.7) 487 (97.0) 1528 (97.0)     
 AA 49 (2.3) 15 (3.0) 47 (3.0) 1.47 (0.78-2.76) 0.232 2.14 (0.93-4.91) 0.074 
         
rs10409299 AA/AG 2026 (93.8) 474 (94.1) 1441 (93.3)     
 GG 135 (6.2) 30 (5.9) 103 (6.7) 0.94 (0.60-1.46) 0.777 1.01 (0.58-1.75) 0.982 
         
rs2071327 TT/CT 1869 (86.9) 426 (85.5) 1355 (87.4)     
 CC 283 (13.1) 72 (14.5) 195 (12.6) 1.15 (0.85-1.56) 0.361 0.90 (0.60-1.35) 0.623 
         
rs460560 TT/CT 2174 (99.6) 510 (99.6) 1562 (99.9)     
 CC 9 (0.4) 2 (0.4) 2 (0.1) 1.62 (0.33-7.91) 0.550 0.12 (0.003-4.47) 0.251 
         
rs17777002 AA/AG 2136 (98.3) 503 (98.8) 1533 (98.8)     
 GG 36 (1.7) 6 (1.2) 19 (1.2) 0.51 (0.19-1.36) 0.180 0.64 (0.22-1.89) 0.418 
                  *Adjusted for age, gender, BMI, WHR, SBP, DBP, total cholesterol, triglyceride, HDL, LDL and 
antihypertensive medication. 
 
 
 
 
